Effect of Hypertension on Nerve Conduction Parameters in Patients Attending Sree Mookambika Institute of Medical Sciences, Kulasekharam by Aswathy, L
 EFFECT OF HYPERTENSION ON NERVE 
CONDUCTION PARAMETERS IN PATIENTS 
ATTENDING SREE MOOKAMBIKA INSTITUTE OF 
MEDICAL SCIENCES, KULASEKHARAM. 
 
 
 
 
Dissertation 
Submitted to 
THE TAMILNADU Dr. M.G.R MEDICAL 
UNIVERSITY 
In partial fulfillment of the requirements for the award of the degree of 
M.D. PHYSIOLOGY 
BRANCH V 
APRIL 2015 
 
CERTIFICATE 
 
This is to certify that this dissertation entitled “ Effectof Hypertension on Nerve 
Conduction Parameters in patients attending SreeMookambika Institute of 
Medical Sciences, Kulasekharam”is a bonafidework done by  Dr. L.Aswathy, 
SreeMookambika Institute of Medical Sciences, Kulasekharam in partial 
fulfillment of the University Rules and Regulation for award of  M.D.Physiology 
[Branch-V] under my guidance  and supervision  during the Academic year 2012-
2015 
Dr. M.S KumariSheela, M.D 
Guide  
Professor and Head 
Department of Physiology 
SreeMookambika Institute of 
Medical Sciences 
[SMIMS]Kulasekharan 
[K.K.District] 
Tamil Nadu - 629161  
  
 Dr. J.Kaniraj Peter, M.D 
Co Guide  
Professor and Head 
Department of Medicine 
SreeMookambikaInstitute of 
Medical Sciences 
[SMIMS]Kulasekharan 
[K.K.District], 
Tamil Nadu – 629161 
 
 
 
 
 Dr. RemaV.Nair, M.D.,D.G.O 
Director 
SreeMookambika Institute of 
Medical Sciences [SMIMS] 
Kulasekharan [K.K.District] 
Tamil Nadu - 629161 
 
 

ACKNOWLEDGEMENT 
In the first place, I extend my sincere thanks to my Professor 
andGuideDr. M.S.KumariSheela, for her valuable guidance and inspiration 
throughout the study. Her patience and understanding during times of 
difficulties in the study period helped me a lot under such circumstances.I am 
grateful for her moral support and encouragement in times of difficulties. This 
study would not have been possible without her help and guidance. I wish to 
thank in gratitude for her untiring,excellent and encouraging suggestions 
throughout the period of work. 
I would place my immense thanks to Dr. Velayuthan Nair, Chairman, 
and Dr. Rema V Nair, Director,for providing facilities to accomplish my 
dissertation work. 
I extend my heartfelt thanks to my ProfessorsDr. P.S. Krishna 
Murthy,and Dr. RajesaNandini for their help and valuable suggestions, 
without whom this work wouldn’t have been possible. 
I also thank my Associate Professor Dr.P.Prabhakar and Assistant 
ProfessorsDr. D.S. Florence Nesabella,Dr.L.MSweety, Dr. K. 
MythiliBai,andMr. Sam for their great support and encouragement in the 
study. 
I thank my colleague Dr.S.Devi, Dr. HosheaJebaRuth.S, Dr. Lisha 
Vincent,Dr.ArchanaChandran, Dr.JiyaMichealfor their help 
andencouragement in proceeding the work. 
The help rendered by the office staff members Mrs. Freeda, Ms. 
Preethy and Ms. SujiDaani is gratefullyacknowledge. 
CONTENTS 
TABLE OF CONTENTS 
Sl. 
No Chapter Page No 
1. Introduction 1-2 
2. Hypothesis 3 
3. Scientific Justification of the study 3 
4. Aim and Objectives 4 
5. Review of Literature 5-44 
 5.1Introduction 5 
 5.1.1    Background Epidemology 5 
 5.1.2    Pathophysiology of Hypertension 6 
 5.1.3    Peripheral Neuropathy 6 
 5.1.4     Molecular aspects of aging Mechanism on nerve conductivity 8-11 
 5.1.5    Pathophysiology of Microvascular complications and its impact 
onnerveConduction 12-13 
 5.1.5.1    Hedghog proteins in diabetic neuropathy and its role in nerve conduction Studies 13-14 
 5.1.6    Age & BMI 14-15 
 5.1.7   Anatomy & Physiology of Peripheral nerve Fibers 15-19 
 5.1.8   Composition of Nerve & Nerve action potentials 20 
 5.1.9   Action Potentials or Nerve impulses 20-21 
 5.1.9.1    Initiation 21 
 5.1.9.2     Propogation of action Potential 22 
 5.1.9.3      Phases in an action potential 22-23 
 5.1.10Myelin and saltatory conduction 23 
 5.1.11Nerve conduction studies 24 
 5.1.11.1Medical uses 24 
                        5.1.11.2  Technique 25 
 5.1.11.3      Motor Nerve conduction study 25 
 5.1.11.4      Sensory Nerve conduction study 26-27 
 5.1.11.5     Principles of Nerve conduction 27-28 
 5.1.11.6      Interpretation of Nerve conduction 29 
 5.1.11.7       Axonal Loss 29 
 5.1.11.8       Normal conduction velocities 30-31 
 5.1.12Clinical studies to substantiate the mechanisms 32-44 
 5.1.12.1 Essential hypertension is as a risk factor associated with microvascular disease 
and neuropathy 32-38 
 5.1.12.2 Impact of age and BMI on nerve conduction velocity 38-42 
 5.1.12.3 BMI as an index of body fat percentage 42 
 5.1.12.4   Obesity mediated oxidative stress 43 
 5.1.12.5   Free fatty acid content and turn over determine the extent of 
oxidative stress in obese subjects 44-57 
6. Materials & Methods 58-81 
 6.1   Study design 58 
 6.2   Study setting 58 
 6.3Time of study 58 
 6.4   Sample size calculation 58 
 6.5   Study groups 59-69 
 6.6   Inclusion criteria 70 
 6.7   Exclusion criteria 70-71 
 6.8   Parameters 71 
 6.9Instrument used 72 
 6.10  Institutional Ethical committee Approval 72 
 6.11 Procedure 72 
 6.11.1   Establishment of BMI 72 
          6.11.2   Establishment of Blood pressure status 73 
          6.11.3   Nerve conduction study evaluation 74 
          6.11.4Motor tibial Nerve conduction study procedure 74-76 
          6.11.5Motor common peroneal Nerve conduction study procedure 76-78 
          6.11.6Sensory superficial peroneal Nerve conduction study procedure 78-79 
          6.11.7Sensory sural Nerve conduction study procedure 80-81 
 6.12 Statistical method of analysis 81 
7. Results 82-98 
       7.1  Study subjects 82 
       7.2   Blood pressure Measurments 83-85 
       7.3    Nerve conduction study 86-98 
                7.3.1   Motor Tibial Nerve conduction variables 86-89 
                7.3.2   Motor Common  peroneal Nerve conduction variables 90-92 
                7.3.3  Sensory Superficial peroneal Nerve conduction variables 93-95 
                7.3.4   Sensory sural Nerve conduction variables 96-98 
8. Disscussion 99-109 
        8.1    BMI & Age 99-100 
        8.2     Blood Pressure 100 
        8.3     Nerve conduction studies 101-105 
        8.4     Molecular pathophysiology pertaining to Nerve conduction variables 105-109 
9.  Conclusion 110 
10.  Summary 111-112 
11. Annexures  
            11.1   Certificate of approval from Institutional Human Ethics Committee(IHEC)  
            11.2   Informed consent Document[ICD]  
 11.3   Case Record Form [CRF]  
            11.4   Image of Nerve Conduction Machine  
            11.5   Abbreviations  
            11.6   Master Chart [ MC]  
 
 List of tables 
Table 
No  
Page 
No 
1. Peripheral Nerve Fiber categories and function 17 
2. Innervation of clinically important muscles 18 
3. Motor Fiber types 30 
4. Sensory fiber types 30 
5. Fiber Types 31 
6. Peripheral Nerves and conduction velocities 31 
7. Grouping of control volunteers and hypertensive patients based onage,BMI,height 61 
 7a.  Control and hypertension subjects with age range of 30-45years,mean BMIand 
height. 61-65 
 7b.Control and hypertension subjects with age range of 50-60 years,mean BMI and  
height 66-70 
8. Basic data and BMI of control and hypertensive subjects for the age range of 30-60  
years 82 
9a. Blood Pressure measurements among control and hypertensives in  Age 30-45 
years 
with  Mean BMI and Mean Height 
84 
9b. Blood Pressure measurements among control and hypertensives in  Age 50-60 
years with Mean BMI and Mean Height 85 
10a. Effect of hypertension on BMI on Motor Tibial Nerve conduction study variables  
in age group of 30-45 years 88 
10b. Effect of hypertension on BMI on Motor Tibial Nerve conduction study variables  
in age group of 50-60 years 89 
11a. Effect of hypertension on BMI on Motor common peroneal Nerve conduction 
study variables in age group of 30-45 years 91 
11b. Effect of hypertension on BMI on Motor common peroneal Nerve conduction  
study variables in age group of 50-60 years 92 
12a. Effect of hypertension on BMI on Sensory superficial peronealNerve conduction 
study variables in age group of 30-45years 94 
12b. Effect of hypertension on BMI on Sensory superficial peronealNerve conduction 
study variables in age group of 50-60 years 95 
13a. Effect of hypertension on BMI on Sensory suralNerve conduction study variables 
in age group of 30-45 years 97 
13b. Effect of hypertension on BMI on Sensory suralNerve conduction study variables  
in age group of 50-60 years 98 
 
 List of figures 
Fig.
No  Page No. 
1. Mechanism of oxidative stress mediated neuronal degeneration in health and 
disease  
2. Anatomical physiology of motor nerve conduction study 26 
3. Anatomical physiology of sensory nerve conduction study 27 
4. Calculation of nerve conduction velocity 28 
5. Description of the study groups 60 
6. Pictorial representation of tibial nerve conduction study: distal nerve 
stimulation 75 
7. Pictorial representation of tibial nerve conduction study:proximal nerve 
stimulation 76 
8. Placement of electrodes and stimulation  site for common peroneal Nerve 
conduction study 77 
9. Pictorial representation of common peroneal nerve conduction study 78 
10. Pictorial representation of sensory superficial peroneal nerve conduction study 79 
11. Pictorial representation of sensory sural nerve conduction study 80 
 
                                                                      ABSTRACT 
Effect of Hypertension on Nerve Conduction Parameters in patients attending Sree 
Mookambika Institute of Medical Sciences, Kulasekharam. 
INTRODUCTION 
The most important medical and public health issue and the single cause of death worldwide is high 
blood pressure.The hypertension prevalence is on a rapid increase now a days.Technological innovations 
are dramatically changing life style of people. Thus according Joint National Committee (JNC – VI) 
hypertension prevalence is 12.5% in South India. Nerve conduction is a constituent of electrophysiological 
test. Nerve conduction study measures duration, latency, amplitude and conduction velocity. Age and BMI 
are important factors that influence hypertension mediated changes in nerve conduction leading to 
peripheral neuropathy. 
 
AIMS & OBJECTIVES  
1.To assess the effect of hypertension on nerve conduction parameters. 
2.  To study the association of age and body mass index on nerve conduction parameters in hypertensive 
patients 
MATERIALS AND METHODS 
A descriptive  cross sectional study of 28  normal subjects and  108 hypertensive patients of more than ten 
years duration with age group between 30-60 years was done and electrophysiological evaluation is done 
for all the subjects by computerized RMS ALERON 401 EMG/NCV/EP system. Latency (m sec), 
Duration, amplitude (mv), conduction velocity (mt sec) of 2 motor nerves (tibial nerve and common 
peroneal nerve) and 2 sensory (superficial peroneal nerve and sural nerve) of both limbs were measured. 
RESULTS  
The results analyzed showed that with increasing BMI, significant blood pressure changes were caused 
along with increasing age. Hypertension causes  significant deterioration of nerve conduction variables  at 
an earlier age. 
CONCLUSION 
Increasing BMI and age caused increased blood pressure and inturn causes slowing of nerve conduction 
variables in the control subjects.Nerve conduction variables were significantly decreased in the 
hypertension with increasing BMI and age; and the onset age of these variables has occurred at an younger 
age. 
KEY WORDS 
Nerve conduction study,hypertension,latency,amplitude,conduction velocity,duration. 
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1. Introduction 
The most important medical and public health issue and the single 
cause of death worldwide is high blood pressure. 
The situation is worse in India, since with modernization, the lifestyle 
is changing and diet is craving for fatty foods rather than healthy traditional 
food, desk bound jobs are replacing physical jobs and stressful city based life 
are replacing calm rural life. Probably due to the ongoing significant increase 
in the Indian hypertensive population; India will next become the 
hypertensive capital following the Diabetic Capital that it has already 
attained.1 The hypertension prevalence is on a rapid increase.2  Reliable 
information should be collected from across the globe from several regions 
that is highly essential to develop International and National health policies, 
which are  important to control or prevent the condition.3 Technological 
innovations are dramatically changing life style of people.Thus according 
Joint National Committee (JNC – VI) hypertension prevalence is 12.5% in 
South India.4 
In 95% of cases essential hypertension is presumed to be a precursor to 
the onset of diabetes.5 Hypertension defines itself as sustained elevation of  
BP > 140/90 mm of Hg. Diagnosis is easy and simple to treat with surplus 
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availability of medications, but sometimes it remains undetected, untreated 
and sometimes the treatment is not adequately effective. 
 Nerve conduction velocity test is an essential, reliable clinical test for 
the diagnosis of the diseases of peripheral nerves that includes peripheral 
neuropathies6,7 
Nerve conduction or electoneurography is a constituent of 
electrophysiological test. That provides reliable and reproducible approaches 
to detect and characterize nerve, muscle or any neuromuscular junction 
diseases.8 Nerve conduction study consist of noninvasive electrical 
stimulation of a peripheral nerve at one site and its non invasive measurement 
of the evoked response at second site in the nerve (sensory or mixed nerve 
conduction) or over the muscle innervated by the nerve (motor nerve 
conduction). 
Nerve conduction study measures duration,latency, amplitude and 
conduction velocity. Conduction velocity and latency denote the speed of 
nerve impulse propagation.They are altered in disease, which causes 
demyelination. Amplitude denote the number of functioning fibers and it is 
altered in diseases causing axonal degeneration.9 
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2.  Hypothesis 
Age and BMI are important factors that influence hypertension 
mediated changes in nerve conduction leading to peripheral neuropathy. 
3.  Scientific Justification of the Study    
After thorough review it was found that several nerve conduction 
studies have been done among normal individuals. Preliminary studies done 
by others on nerve conduction velocity based on age in healthy individuals 
proved that age could modulate definitely the amplitude and duration of 
motor & sensory nerves.10 Study based on body mass index (BMI) showed 
that BMI could affect nerve conduction parameters,11,12and there are very 
limited studies across the world in nerve conduction  among hypertensives. 
Hence there is a need to look into these parameters on hypertensives so that 
people can be made aware of the complications arising as an outcome of 
hypertension.  
The theme of 2013 is High blood pressure as projected by world health 
organization(WHO).The definitive goal is to create greater alertness, 
healthybehaviour,better detection and facilitating environments. 
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4.  Aim and Objectives 
1.   To assess the effect of hypertension on nerve conduction 
parameters. 
2.  To study the association of age and body mass index on nerve 
conduction parameters in hypertensive patients. 
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5. Review of literature 
5.1 Introduction 
   5.1.1 Background and Epidemiology 
Blood pressure(BP) is clinically defined as the lateral pressure exerted 
by the column of blood on the walls of the arteries.13 Cardiovascular 
healthcare systems in India is highly pressurized by the elevated prevalence of 
hypertension in the common public.14,15 Global data analysis assessing the 
burden of hypertension, presents 20.6% men and 20.9% women are distressed 
from hypertension in the year 2005 in India.16 The rates for hypertension in 
percentage is projected to increase to 22.9% and 23.6%(men and women), in 
India by 2025.15 Recent Indian prevalence studies in hypertension show a 
population ratio of 33% in urban and 25% in rural. 17-19 
 Prevalence of raised BP in Indians has been shown to be 32.5% in men 
and 31.7% in women as estimated by the WHO in 2008.20 Hypertension is 
perceived to be the third leading killer in the India; as hypertension related 
illness causes 1 in 8 deaths as estimated by World Health organization.21 Thus 
Hypertension qualifies itself as an important area of medical research. 
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5.1.2 Pathophysiology of Hypertension  
Pathophysiology and Molecular pathophysiology of hypertension still 
remains indecisive. Two to five percent of hypertensives have an essential 
renal or adrenal cause for their raised blood pressure, known as secondary 
hypertension. When hypertension has no single exclusive factorial cause the 
condition is termed essential hypertension.22 Even though there are no direct 
causes for essential hypertension there are several risk factors that contribute 
towards its development. The most important of which are: surplus body 
weight, high dietary sodium intake, decreased physical activity, insufficient 
fruit and vegetable intake,excessive alcohol abuse.23 
5.1.3 Peripheral Neuropathy 
Pain perception is observed to be decreased in hypertensive subjects.24 
Rat Psychophysiological studies presented an association to hypalgesic 
behavior (delayed response by a limb to applied noxious stimuli such as a hot 
plate, electrical shock, or mechanical force) in arterial hypertension.25-32Zamir 
and Shuber illustrate that hypertensive subjects have increased tolerance to 
pain, that was assessed by graded electrical tooth pulp stimulation.33 There is 
relatively evidence that hypertensive individuals may have peripheral 
neuropathy.34-44 
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Central inhibition of nerve impulses occurs in the peripheral nervous 
system(PNS)during peripheral neuropathy. The PNS nerves lie exterior to 
central nervous system innervating the limbs and organs; and is divided into 
Voluntary nervous system (somatic) and Involuntary nervous system 
(Autonomic). Incidence of peripheral neuropathy is around 2.4 that rise with 
age to 8%.45 
 Indian incidence of peripheral neuropathy has been documented in 
studies related to diabetes. There is a higher incidence of diabetes mellitus in 
India (4.3%)46 when compared with the West(1-2%).47 The incidence of 
Diabetic neuropathy in Indian scenario has not been epidemiologically 
exploited in studies; but a south Indian study presents 19.1% of type II 
diabetic patients present peripheral neuropathy48, and very few study was 
done on the association of hypertension with peripheral neuropathy.49-53 
What causes peripheral neuropathy? 
• Autoimmunity (Inflammatory demyelinativepolyradiculoneuropathies). 
• Vasculitis (Connective tissue diseases) 
• Systemic illness (diabetes, uremia, sarcoidosis, myxedema, acromegaly). 
• Cancer (paraneoplastic neuropathy) 
• Infections (diphtheria, leprosy, lyme disease, AIDS, herpes zoster). 
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• Dysprotenemia (myeloma, cryoglobulinemia) 
• Nutritional deficiencies and alcoholism. 
• Compression and trauma. 
• Toxic Industrial agents and drugs. 
• Inherited neuropathies. 
Oxidative stress and aging mechanisms are factors that can have 
definite impact on nerve conduction; the mechanisms pertaining to this have 
been clearly worked out with aged people54 and in type II diabetic 
subjects.55However, not much study has been documented with 
hypertension.Though our study does not directly measure any aging 
parameters or oxidative stress parameters; references obtained will be used to 
back up our clinical study findings. 
5.1.4 Molecular aspects of aging mechanisms on nerve conductivity 
 Advancing age, mediates changes in the vasculatures function and 
structure destruction. In precise, modification in endothelial cell functions 
relates to alter the expression and release of the vasoactive mediators such as 
nitric oxide and endothelin-1.55Additionally antithrombotic and vasodilatatory 
function of the endothelium decline with age, while inflammatory processes 
and oxidativestressincreases.This process is enhanced with the presence of 
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cardiovascular risk factor such as hypertension, appears to happen at an 
earlier age when compared to normal subjects56 
Nitric oxide levels, is vital for the endothelial membrane integrity and 
its function.The biological levels of Nitric oxide diminishes with age leading 
to dysregulated vascular nature thus promoting proatherosclerotic and 
prothrombotic environment.57,58,59 Different studies based on animal models, 
and clinical trials have accumulated evidence proving that aging augments 
production of reactive oxygen species (ROS) in several tissues that includes 
the endothelium.60,61 
Aging induced vascular oxidative stress appears to be connected with a 
worldwide increased pro-oxidant setting represented by augmented 
expression of inducible nitric oxide synthase,62 NAD(P)H oxidases63 and a 
down-regulation of antioxidant systems such as the superoxide dismutases.61 
The increased ROS production observed with increased aging mediates a 
massive amount of detrimental effects. Critical functional importance of 
increased ROS production is to scavenge nitric oxide by superoxide (O2-) to 
synthesize peroxynitrite(ONOO-).64,65ONOO- is labile that easily penetrates 
the phoshoplipid membrane and produces substrate nitration, thereby 
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inactivating vital regulatory receptors,and enzymes mainly antioxidants that 
scavenge free radicals.66 
The extreme decrease in nitric oxide levels during aging is aggravated 
by the endothelial nitric oxide synthase expression and a reduced levels of 
intracellular L-arginine.67 Recent findings propose that nitric oxide production  
declines with aging that ultimately enhances endothelial cell apoptosis.68 
 The accelerated production of ROS  giving rise to superoxide anion 
(O2-), hydroxyl radicals, hydrogen peroxide and/or reactive nitrogen species, 
like peroxynitrite (ONOO-), observed with aging is not only thought to be 
implicated in nitric oxide scavenging; but is directly implicated in the 
upregulation of pro-inflammatory processes,like activating NF- κB (Nuclear 
Factor)  that transcribes inflammatory factors, that activate the macrophages.69 
 Telomeres serves as important marker in cellular senescence and 
vascular aging70. Telomeres are DNA-protein complexes found at the ends of 
chromosomes and important for replication mechanisms.They are observed to 
be shortened in senescent cells as a consequence of mitochondrial ROS 
overproduction. In this setting, telomerase reverse transcriptase (TERT) is 
phosphorylated by src kinase that exports TERT from the nucleus to the 
cytoplasm.71,72 During DNA replication and cell division telomeres in 
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chromosomes are shortened.This process is usually compensated by TERT. 
Aging-induces a lack of nuclear TERT activity leading to cellular senescence 
that occurs as a consequence of excessive telomere shortening, resulting in 
chromosomal instability that leads to the onset of apoptosis. 
Apoptosis not only occurs in the vascular cells but can occur in the 
nervous cells73also.Thus we hypothesis these mechanisms should have a role 
in hypertension provoked peripheral neuropathy. 
Demyelination and Neuronal cell loss are processes that occur during 
aging and these processes culminate into cognitive function decline in the 
central nervous system and these studies are well documented74. However age 
related changes in the peripheral nervous system have very little accounting 
as clinical and rat model studies.The impact of oxidative stress has been 
acknowledged to affect peripheral nerves in rat model studies75 and clinically 
well documented in diabetic neuropathy76 
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5.1.5 Pathophysiology of microvascular complications and its impact on 
nerve conduction  
Similar to our understanding of macrovascular complications, it is 
becoming increasingly clear that microvascular complications share a 
common pathophysiology and it has been well documented in diabetes. 
1. Increased polyol pathway activity leading sorbitol and fructose 
accumulation, NAD(P)H- redox imbalances, and changes in signal 
transduction. 
2. Nonenzymaticglycation of proteins yielding advancedglycation end-
products (AGEs) 
3. Activation of PKC thereby initiating a cascade of stress responses, and 
Increased hexosamine pathway flux 77.    
The unified mechanism of tissue damage arising by combining the 
above mechanisms indicates hyperglycemia-mediated superoxide 
overproduction by the mitochondrial electron transport chain. If superoxide 
accumulation or euglycemia is inhibited restoration of the metabolic and 
vascular imbalance occurs that blocks both the initiation and progression of 
complications77. 
Unchecked superoxide accumulation triggers increase in polyol 
pathway activity, AGE accumulation, PKC activity, and hexosamine flux that 
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act as a feed forward system for progressive cellular dysfunction.Neural 
function is disorganized when neurotrophic factors that support regeneration 
of a nerve are lost due to metabolic and vascular disturbances.This loss on 
long term, can mediate apoptosis of neurons, Schwann cells and glial cells of 
the peripheral nervous system.77 Depletion of nerve growth factor (NGF), 
neurotrophin-3 (NT-3), ciliaryneurotrophic factor, and IGF-I have been well 
documented78. 
5.1.5.1 Hedgehog proteins in diabetic neuropathy and its role in nerve 
conduction studies 
The animal model study conducted calcutt and his colleagues proved 
that experimental diabetes induced decreased expression of dessert hedgehog 
protein that was accompanied with depletion of neurotrophic factors which in 
turn was accompanied by slowing of conduction velocities in the motor nerve 
and sensory nerve. This is due to the fact that dessert hedgehog protein is 
involved in the patterning of the peripheral nerves in developing embryo, and 
later involves itself in regeneration of the peripheral nerves in adult.They also 
showed that injection of hedgehog protein for 5 weeks restored motor and 
sensory nerve conduction velocities. From this study we understand that 
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diabetes mediated oxidative stress causes the downregulation of dessert 
hedgehog proteins and neurotrophic factors77.       
Increased Advanced glycation End products, and enhanced PKC 
activity has been well documented in hypertension also.79,80 Though 
hexoseamine pathway has been documented in diabetes it could be altered in 
hypertension also,sincehexoseamine pathway has been correlated with insulin 
resistance and insulin resistance has been well documented in hypertension.81 
5.1.6 Age and BMI 
Another crucial factor is as age increases the bioavailability of nitric 
oxide decreases and the potential role of Angiotensin II having the 
vasoconstrictor activity increase. Angiotension II has been documented to 
increases sensence.82 
Body fat is calculated as BMI derived from the height and weight in 
adult men and women. Thus it has been proved by others that higher body 
mass index is associated with higher incidence of mortality in aged people.83 
Based on this we hypothesized that BMI,a measure of fat could aggravate the 
mechanisms of aging in a more rapid manner.In people with hypertension the 
onset of  BMI mediated aging mechanisms could occur at an earlier age.  
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Though many studies are going on to relate hypertension to peripheral 
neuropathy none of them have been able to establish a link directly because 
the mechanisms that occur are of very slow process and it make years to show 
clear manifestation as an clinical outcome in hypertension,whencompared to 
diabetic patients  where  hyperglycemia manifests these mechanisms in a 
faster manner leading to deleterious effects.  
5.1.7 Anatomy and Physiology of Peripheral Nerve Fibers 
Peripheral nervous system is made up of several constituents. The 
nerve roots of plexi and peripheral nerves are innervated by sensory and 
motor (axons). Dorsal root ganglia typically posses cell bodies, which are 
located local to the spinal cord. Muscle fibers near the neuromuscular junction 
and/or muscle spindles are the points where the nerve fibers terminate (these 
sites are points where muscle sensitivity to stretch is located).84 The peripheral 
nerves are not only made up of the nerve fibers but they also consist of 
several layers of connective tissue called the endoneurium, perineurium and 
epineurium and they are supplied by blood vessels. 84 
Axons that are either myelinated/unmyelinated give rise to the 
individual nerve fibers. Schwann cells synthesize the myelin in the peripheral 
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nervous system, and the myelin adheres to the nerve cell membranes 
wrapping it in several layers.84 
The myelin is consequently adhered by several layers of Schwann cell 
membrane, providing an electrical insulation to the lipid-rich myelin layer. 
The nodes of Ranvier appear between the Schwann cells and at these points in 
the nerve fiber myelin is absent. These points contains of high density of 
voltage-gated sodium ion channels which mediate membrane depolarization.84 
Myelin increases the velocity of conduction in a nerve, with the 
distance between two adjacent nodes of Ranvier determining the velocity of 
the conduction in a nerve.84 
Conduction velocity to some extent determines the nerve fibres 
function (Table 1). Large nerve fibres that are heavily myelinated make up 
mostly the somatic motor axons. Sensory nerve fibres that innervate muscle 
spindle (stretch) and Golgi tendon organ (tension) receptors are also heavily 
myelinated. Touch, proprioception and joint position sense are attributed by 
the Intermediate nerve fibers. Pain sensation that is sharp and the motor 
function that appears from autonomic preganglion are taken care of by the 
lightly myelinated fibers. Functions mediated by the most heavily myelinated 
nerve fibers tend to be affected primarily when myelin is degraded by 
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pathologic processes having a profound effect on the conduction rate of the 
nerve.85 
Table 1: Peripheral Nerve Fiber Categories and Functions 
Fiber category 
Size 
(microns) 
Speed 
(meters/second) 
Function 
Aα; Group IA and IB 
afferents 
15 60-100 
Large motor axons, Muscle stretch and 
tension sensory axons 
Aβ;Group II afferents 12-14 30-60 
Touch, pressure, vibration and joint 
position, sensory axons 
Aγ 8-10 15-30 Gamma efferent motor axons 
Aδ;Group III 
afferents 
6-8 10-15 
Sharp pain, very light touch & 
temperature sensation 
B 2-5 3-10 Sympathetic preganglionic motor axons 
C; 
Group IV afferents 
<1 <1.5 
Dull, aching, burning pain and 
temperature sensation 
 
Continuous mode of propagation of electrical signal in a very slow 
manner occurs in unmyelinated nerve fibres represented as non-saltatory 
conduction, Burning pain, temperature sensation and soreness including the 
sympathetic, postganglionic motor nerves are conveyed by these fibers. Their 
speed is roughly 1 meter/second.84 
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To analyze the disorders affecting peripheral nerves and its accurate 
diagnosis,it is vital to remember the anatomical distribution of motor and 
sensory fibers as presented in Table 2.85 
Table 2:  Innervation of Clinically Important muscles 
Movement tested Main muscles Nerve roots Peripheral nerve 
Shoulder    
Shrug (elevation) Trapezius C2-5 Spinal accessory 
Abduction Deltoid/supraspinatus C5(6) Axillary/suprascapular 
External rotation Infraspinatus/teres C5(6) Suprascapular 
Internal rotation Pectoralis major C5-7 Lateral pectoral 
Adduction Latissimus/pectoralis C6-8 Suprascapular/pectoral 
Flexion Deltoid C5-6 Axillary/musculocut. 
Elbow    
Flexion Biceps/brachialis  Brachioradialis 
C5-6  
C5-6 
Musculocutaneous 
Radial 
Extension Triceps C6-7 Radial 
Wrist    
Flexion Flexor carpi radialis Flexor carpi ulnaris 
C6-7 
C7-8 
Median 
Ulnar 
Extension Extensor carpi radialis Ext. carpi ulnaris 
C6-7 
C7-8 
Radial 
Deep radial 
Pronation Pronator teres C6-7 Median 
Supination Supinator Biceps 
C5-6 
C5-6 
Radial 
Musculocutaneous 
Finger    
Flexion Flexor digitorum mm. C7-8 Median (ulnar) 
Extension Extensor digitorum C7-8 Deep Radial 
Ab- & Adduction  Interosseous muscles C8-T1 Ulnar 
Thumb abduction  Abductor pollicis br. C8-T1 Median 
Hip    
Flexion Iliopsoas L2-3 (L4) Lumbar plexus 
Extension Gluteus max L5-S2 Inferior gluteal 
Abduction Gluteus medius L5-S1 Superior gluteal 
Adduction Adductor mm. L2-4 Obturator 
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Stable resting membrane potential maintained by sustained ion 
gradients traversing the axonal membrane is critically required for nerve fiber 
survival. Normal membrane integrity of the constituents is required for 
supporting the ion gradients84.  
The neuron requires a large amount of energy to generate ion gradients 
and energy for transporting the moving constituents from the cell body down 
and up the axon. All these processes need a high blood flow rate to the nerve. 
Ischemia or Diminished blood flow to the nerves is poorly tolerated by them. 
Peripheral nerve function is mainly dependent on axonal transport.  
Nerves receive innervations from the nervinervorum that are sensory or 
motor derived from the sympathetic nervous system. Innervations density is 
not consistent and likely differs with the precise nerve in question as well as 
Knee    
Flexion Hamstring L5-S1 Sciatic 
Extension Quadriceps L2-4 Femoral 
Ankle    
Dorsiflexion Tibialis anterior L4-5 (S1) Fibular (peroneal) 
Plantar flexion  Gastroc/soleus S1 (S2) Tibial 
Inversion Posterior tibial L5 (S1) Tibial 
Eversion Fibular (peroneal) L5 (S1) Fibular (peroneal) 
Great toe    
Dorsiflexion Extensor hallucis L5 (S1) Fibular (peroneal) 
Plantar flexion  Flexor hallucis (S1) S2 Tibial 
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with the site along the nerve. The fibers may be associated with nerve induced 
pain. 
5.1.8 Composition of Nerves and Nerve Action Potentials 
Action potentials that arise by simultaneous stimulation of all nerve 
fibers is a summation of individual nerve fibers are called compound nerve 
action potentials (NAP).NAP's are clinically recorded routinely corresponding 
to large myelinated fibers from which the nerve conduction velocity can be 
calculated85 
5.1.9 Action Potentials or Nerve impulses 
“Nerve impulses” or “spikes” are other names that are given for action 
potentials. Spike trains are the chronological chain of action potentials 
generated by a neuron.A neuron that produces an action potential is supposed 
to fire. 
Nerve cell’s plasma membrane is embedded with special type of 
voltage-gated ions channels that generate action potentials. The ion channels 
remain closed when the membrane potential is in resting, but they quickly 
open if the membrane potential increases to exactly beyond a defined 
threshold value. When the channels open there is depolarization in the 
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transmembrane voltage, and at this point sodiuminflowoccurs.This changes 
the electrochemical gradient, giving rise to further increasing the membrane 
potential. This change in membrane potential triggers additional ion channels 
opening, yielding a larger electric current across the cell membrane84.  
The membrane potential keeps rising till all the ion channels open up 
resulting in a large increase in the membrane potential. The plasma membrane 
polarity reverses due to the rapid influx of the sodium ion. Following this 
process potassium channels set off, and potassium ions flow externally 
reinstating the electrochemical gradient and thus returning the nerve axon to 
the resting state.  
Hyperpolarization or refractory period is a brief negative shift that 
occurs after an action potential.This occurs as phenomenon of added 
potassium currents. The mechanism prevents action potential from reversing 
back in its movement. 
5.1.9.1 Initiation 
For the initiation of action potential the membrane voltage at the axon 
hillock should be raised above the threshold for firing to occur.86 
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5.1.9.2 Propagation of action potential 
The action potential once formed is regenerated at regular intervals to 
be transmitted from the initial segment of the axon to the axon terminal.This 
is known as propogation of action potential.The speed of conduction of the 
impulse depends on myelination and diameter of the axon.Conduction 
velocity is more in myelinated axon and is proportionate to the diameter of 
the fibrer.13 
5.1.9.3 Phases in an action potential 
A typical action potential has a phase of depolarisation and a phase of 
repolarisation.Phase of depolarisation is recorded as asharp upward wave 
during which the membrane potential approaches zero and then attains a 
positive value.It consists of slow depolarisation to threshold (local 
response),rapid rising phase,overshoot and a peak. 
           The phase of repolarisation is recorded as downstroke during which the 
membrane potential returns to the resting level.It includes a rapid falling 
phase and a slower terminal part called after depolarisation.The phase of 
repolarisation is followed by an after hyerpolarisation phase during which the 
membrane potential undershoots and then returns back to the resting level. 
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The depolarisation and repolarisation phase of the action potential can 
be explained by sequential changes in membrane permeability to sodium and 
potassium leading to large fluxes of these ions across the membrane, along 
their gradients.Depolarisation is due to opening of voltage gated Na+ 
channels,causingmassive influx of sodium ions.Repolarisation is due to 
opening of voltage gated k+ channels causing efflux of K+.13 
5.1.10 Myelin and saltatory conduction 
Myelin sheaths cover the neuronal axons that mediate electrical signals 
that are fast and effective in the nervous system.   
Membrane capacitance is reduced and membrane resistance increased 
by myelin sheath at the inter-node intervals.Thussaltatory movement of action 
potentials occurs in a fast rate from node to node.  
Myelinated axons prevent the ions from entering or leaving the axons 
due to the presence of myelin sheaths that increases conduction velocity 
making the action potentials more energy efficient. With increasing axonal 
diameter action potential increases.87 
Some diseases degrade myelin and impair saltatory conduction, 
reducing the conduction velocity of action potentials.Breakdown of myelin 
impairs coordinated movement in multiple sclerosis.88 
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5.1.11 Nerve conduction studies89 
Motor and sensory nerve conduction in the humans is medically 
detected by NCS (Nerve conduction study). Nerve conduction velocity (NCV) 
is a mutual measurement observed during this study. 
5.1.11.1 Medical uses 
Parathesis (numbness, tingling, burning) and or weakness of the arms 
and legs are mainly evaluated by nerve conduction studies. 
Some of the common disorders that can be diagnosed by nerve 
conduction studies are 
 Peripheral Neuropathy 
 Peroneal Neuropathy 
 Spinal disc herniation 
 Tarsal Tunnel Syndrome 
 Ulnar neuropathy 
 Carpal tunnel syndrome 
 Cubital tunnel syndrome 
 Gullian-Barré syndrome 
 Guyon’s canal syndrome 
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5.1..11.2  Technique 
The nerve conduction study consists of the following components 
 Motor NCS 
 Sensory NCS 
5.1.11.3  Motor NCS 
NCS of the motor nerve is done by stimulating the motor nerve and 
recording the response from its target muscles (Figure 2). The electrical signal 
recorded from stimulation of a motor nerve is called compound muscle action 
potential- CMAP which is generated by the muscle and it is usually large. 
“Terminal latency” is a term given to the amount of time taken before muscle 
depolarization starts. 
Abnormal prolongation of this value is often of benefit in the detection 
of distal entrapment neuropathies.  
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Figure 2:  Anatomical physiology of the Motor Nerve conduction study 
 
 
 
 
 
 
 
5.1.11.4  Sensory NCS 
When purely sensory portion of the peripheral nerve (posterior ankle) is 
stimulated and the recordings are taken it is called SNAP (Figure 3). 
Sensory amplitudes are much lesser than the motor amplitudes 
expressed in microvolt (µV),in contrast to the millisecond reading observed in 
the motor nerve. NCV of the sensory nerve is worked out based upon the 
distance between the stimulating electrodes and latency. 
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Figure 3:  Anatomical physiology of the sensory nerve conduction study 
 
 
 
 
 
 
 
5.1.11.5  Principles of nerve conduction89 
An electrode pair is used to stimulate impulse on one end and the other 
is used to record the response further down along the path of the nerve for 
motor nerves distally and proximally in the sensory nerves. A depolarizing 
square wave current is applied to the peripheral nerve to produce a compound 
muscle action potential (CMAP) which shows the summation of activated 
muscle fibers. Sensory nerve action potential (SNAP) describes the output 
that is summation of the electrical stimulation given to the sensory nerve.  
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The parameters obtained and used for interpretation include (Figure 4 
shown below) 
• Amplitude-From baseline to peak (reflects the number of 
conducting fibers and is reduced in axonal loss) 
• Latency (ms)-From stimulus to onset of evoked response  
Figure 4: Calculation for Nerve conduction Velocity 
 
 
 
 
 
• Duration of response (ms) 
• Conduction velocity (m/s)- Calculated from the distance between 
stimulation and recording points, divided by latency (reflects 
integrity of the myelin sheath important for impulse conduction and 
is reduced in demyelinating processes). 
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5.1.11.6  Interpretation of nerve conductions89 
When interpreting NCS data, initial considerations are: 
• Is the CMAP or SNAP amplitude is normal in size and shape or 
reduced? 
• Is the conduction velocity normal? 
5.1.11.7 Axonal loss 
Axonal loss results in the reduction of compound amplitude reflection 
in lesser functioning axons.  
If only there is axonal injury, and if the myelin sheath is not injured the 
remaining axons conduct with normal latencies and velocities, but if the 
axonal degeneration proceeds,the latencies and velocities can be slightly 
prolonged.It is an outcome of the loss of larger and fast conducting fibers.    
Loss of myelin slows conduction which manifests as significant 
reduction in conduction velocities and temporal dispersion (increase in the 
duration). Conduction block can also occur (a reduction of area/amplitude of 
at least 50% at a proximal compared to a distal site of stimulation). 
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5.1.11.8 Normal Conduction Velocities85 
The tables 3, 4, 5 represent the normal conduction velocity of the motor and 
sensory nerve fibers.Depending on the function nerves are classified  
according to Erlanger Gasser asmotor,sensory and secretomotor.Depending 
on myelination, they are classified as myelinated and unmyelinated. 
Table 3:  Motor Fiber types 
Type Erlanger-Gasser 
classification 
Diameter Multiple Conduction 
velocity 
Associated Muscle 
fibers 
α A α 13-20 µm Yes 80-120 m/s Extrafusal muscle fibers 
β A β 5-8 µm Yes 4-24 m/s Extrafusal muscle fibers 
Table 4:  Sensory fiber types 
Type Erlanger-
Gasser 
Classification 
Diameter Myeli
n 
Conduction 
velocity 
Associated sensory receptors 
Ia Aα 13-20 mm Yes 80-120 m/s Responsible for proprioception 
Ib Aα 13-20 mm Yes 80-120 m/s Golgi tendon organ 
II Aβ 6-12 mm Yes 33-75 Secondary receptors of muscle 
spindle. All cutaneous 
mechanoreceptors 
III Aδ 1-5 mm Thin 3-30 m/s Free nerve endings of touch and 
pressure.Nociceptorsof 
neospinothalamic tract. Cold 
thermoreceptors 
IV C 0.2-1.5 mm No 0.5 2.0 m/s Nociceptors of paleopsinothalamic 
tract. Warmth receptors 
 
 
  Review Of Literature 
31 
 
Table 5:  Fiber types 
Type Erlanger-Gasser 
Classification 
Diameter Myelin Conduction 
velocity 
Preganglionic 
fibers 
B 1-5 mm Yes 3-15 m/s 
Postganglionic  C 0.2-1.5 mm No 0.5-2.0 m/s 
 
Table 6 shows the normal conduction velocity of some of the peripheral 
nerves such as median sensory nerve,median motor nerve,ulnar sensory 
nerve,ulnar motor nerve,peroneal motor nerve,tibial motor nerve,sensory sural 
nerve. 
Table 6:  Peripheral Nerves 
Nerve Conduction Velocity 
Median Sensory 45- 70 m/s 
Median Motor 49-64 m/s 
Ulnar sensory 48-74 m/s 
Ulnar motor 49+ m/s 
Peroneal Motor 44+ m/s 
Tibial Motor 41 + m/s 
Sural Sensory 46-64 m/s 
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5.1.12 Clinical Studies to substantiate the mechanisms explained above. 
5.1.12.1 Essential hypertension is identified as a risk factor 
associated withmicrovascular diseases and neuropathy: 
A study conducted by Anchalaet al90 was a meta analysis paper to 
assess the prevalence of hypertension in India. Their results suggests 29.8% 
as overall prevalence of hypertension in India. Significant differences were 
found between the rural and urban population as 27.6% and 33.8% 
respectively. Regional estimates for the prevalence of hypertension were as 
follows: rural north, east, west and south India were 14.5%, 31.7%, 18.1%, 
and 21.1% respectively,whereas the urban sector presented 28.8%, 34.5%, 
35.8% and 31.8%, for north, east, west and south. Overall awareness, 
treatment and control of BP were 25.3%, 25.1% and 10.7% for rural Indians 
and 42.0%, 37.6%, 20.2 for urban Indians. Thus the study in conclusion 
predict that 33% and 25% rural Indians are hypertensive. Of them 25% rural 
and 42% urban Indians are aware of their hypertensive status. Only 25% rural 
and 38% of urban Indians are being treated for hypertension. One-tenth of 
rural and one-fifth of urban Indian hypertensive population have their BP in 
control. 
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A study was done by Dhafir I. EI- Yassinet al51 to assess the 
relationship between hypertension and peripheral neuropathy. The study 
included 25 normal subjects and 75 hypertensive patients. The study assessed 
nerve conduction variables of sensory nerve conduction variables of sensory 
nerve function, motor nerve function and also F-wave measurement. They 
observed statistical significance of (p<0.05),for the association between 
hypertension patients and sensory nerve conduction that presented 
deterioration. However, the nerve conduction studies (Median, Ulnar, Tibial) 
did not show much changes; whereas, in their F-wave parameter assessment 
the latency of the slowest F-wave was observed in the common peroneal 
nerve which was prolonged. From their results they interpret that smallest 
fibres were affected in hypertension. 
Legrady P et al91 presented that non-diabetic hypertensive patients also 
present the complications presented in diabetes. In their study they recruited 
18 Hypertensive who were non-diabetic and 10 patients who were type 2 
diabetic who also had hypertension. These two groups were compared with 11 
normal healthy controls. Patients who presented hypertension were 
undergoing antihypertensive therapy. Cardiac autonomic neuropathy using 
Ewing method was detected in all patient groups. The peroneal nerve 
presented current perception threshold values of 250 Hz 
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inhypertensiveswhowere non-diabetic and the diabetics presented threshold 
values of 250 Hz and 5 Hz when compared to the control subjects. These 
values where higher than the control. Their study supports that the 
development of neuropathy is mainly dependent on vascular factors. 
An experimental study done by Gregory et al92 observed Behavioral, 
physiological and structural indices of neuropathy for a period of six months 
in spontaneously hypertensive and age matched normotensive rats with or 
without concurrent streptozotocin induced diabetes. There results predict that 
spontaneously hypertensive rats presented nerve ischemia, thermal 
hyperalgesia, nerve conduction slowing and axonal atrophy.The 
supernumerary Schwann cells of thinly myelinated fibers were indicative of 
cycles of demyelination and the remyelination was observed along with 
reduced levels of myelin basic protein in the nerves. Similar disorders were 
evident in streptozotocininduceddiabetic rats,wheremyelinated thin fibers 
were not observed and myelin basic protein is normal. Thus they perceive that 
rats presenting combined insulinopenia, hyperglycemia and hypertension 
provide a model for diabetic neuropathy which offers an opportunity to study 
the Schwann cell pathology mechanism and thus they suggest that 
hypertension could contribute to the pathology of diabetic neuropathy.  
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A clinical study was done by Shilpa K et al93 on Auditory Brainstem  
responses and nerve conduction velocity in essential hypertensive subjects. 
Their study included 20 control subjects and 20 patients with primary 
hypertension in the age group between 40-60 yrs who were age and sex 
matched. They assessed the auditory brainstem responses (ABR) and nerve 
conduction velocity(NCV) of both sensory and median Ulnar nerves.They 
conclude that high blood pressure did cause a deficit in the auditory pathway 
sensory conduction in the brainstem. However their studies did not report any 
changes in the motor and sensory nerve conduction in the median nerve in 
essential hypertensive patients. 
Another study reported by Edwards et al94 presents that essential 
hypertension may be due to impaired nerve function. This study was done in 
30 patients with unmedicated essential hypertension and 29 normotensives. 
They examined cutaneous sensory thresholds, median nerve (sensory and 
motor)  conduction velocities and median nerve sensory action potential 
amplitudes. The authors observed that higher thresholds in cutaneous sensory 
thresholds and amplitudes of the sensory action potentials were smaller in the 
hypertensive subjects when compared to normotensives. However, they did 
not observe nerve conduction velocity changes in both sensory and motor 
nerves between the control and hypertensive subjects. Thus from these results 
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they infer that  hypertensive  patients presents  subclinical axonal neuropathy 
of sensory afferents, thereby reducing active sensory nerve fibers without 
affecting myelination and this accounts for the perceptual deficits that 
characterize hypertension.  
Another study done by Viskoperet al95 on 52 hypertensive patients and 
10 control subjects. They observed that in the hypertensive subjects nerve 
conduction velocity decreased with increasing blood pressure and changes in 
the retina. Their mean conduction velocity as observed in the hypertensive 
subjects was 45.4 m/sec that was ranging from 29.5 to 60 m/sec, when 
compared to the range of control subjects that was observed to be between 54 
to 60 msec. 
Though a positive correlation between hypertension and nerve 
conduction velocity has presented by certain authors; certain others conflict 
with this idea and have presented papers showing no correlation between 
hypertension and nerve conduction velocity as discussed below with clinical 
trials.   
A study done by Shubangiet al96 to assess the motor and sensory nerve 
conduction of the median nerve in thirty essential hypertensive patients in the 
age range of 40-60 years along with thirty age and sex matched controls. In 
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the Normotensive group the sensory nerve conduction was 60 ± 2.82 and in 
the hypertensive group 60.35 ± 2.78. The motor nerve conduction was 
observed to be 58.60 ± 4.10 in the normotensives and 57.75 ± in the 
hypertensives. However, the authors admit that extensive studies need to be 
done to confirm these findings. 
Cho D Y et al97presents a longitudinal study of 584 hypertensive 
subjects (primary care patients) who were 65 years and older. These patients 
presented none of the 10 medical conditions known to cause peripheral 
neuropathy. These patients were assessed for the presence of peripheral 
neuropathy by the following examinations. The patients history was recorded 
with other following basic data like the number of hypertensive drugs being 
taken, systolic blood pressure, diastolic blood pressure, pulse pressure and 
orthostatic hypertension were measured. Also they assessed the impact of 
specific class of antihypertensive drugs and NSAIDs (Non-Steroidal anti-
inflammatory agents) in their follow up after 3 years.History of hypertension 
was shown to be negatively associated with age related peripheral neuropathy, 
but not the hypertension variables as reported by them (Odds Ratio 0.60, 95% 
CI 0.40 to 0.90).They also perceive that in diabetic patients,hypertension had 
a protective effect on peripheral neuropathy. However, the current pulse 
pressure (Odds Ratio 1.03, 95% CI 1.0 to 7.05) was a positive predictor of 
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peripheral neuropathy in the diabetic subjects. These results are obtained by 
the authors after adjusting for age and BMI. In their 3rd year of assessment 
287 patients using β-blocking agents (OR 3.56; 95%, CI 1.08 to 8.03) and 
NSAIDS (OR 2.65; 95% CI 1.37 to 5.10) also associated positively to age 
associated peripheral neuropathy(AAPN). They concluded  stating that they 
could not infer why hypertension had a negative correlation with nerve 
conduction velocity.    
5.1.12.2  Impact of Age and BMI on nerve conduction velocity 
Though hypertension related studies have a conflict of interest in the 
hypothesis that hypertension could cause slowing in the motor and sensory 
nerve conduction,the leading causative factors such as BMI and age 
influencing the onset of peripheral neuropathy has been clearly demonstrated 
to have an impact on nerve conduction variables by various  studies 
conducted in normal subjects.  
Friedrich B and Fritz Bet al.98conducted a study on healthy individuals 
in the age range of 15 to 72 years. The study established the normal values for 
the distal and proximal segments for superficial peroneal nerve, sural nerve 
and posterior tibial nerve. The values were obtained from 71 healthy subjects. 
The authors presented electronic averaging that was used to analyze the slope 
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of the potentials. It was observed that distal values (lower extremities) were 
one tenth of those measured at the proximal end (upper extremities). The 
values 56.5± 3.4 m/sec was observed at the proximal segment and 46.1 ± 3.7 
m/sec at the distal segment of the nerves.These values were observed as the 
maximum sensory conduction velocity in age range of 15 to 30 years. With 
increasing age of 40 to 65 years,the values showed slowing of conduction 
both proximally and distally (proximal conduction velocity (53.1 ± 4.6 m/sec) 
anddistal conduction velocity(42.5 ± 5.5 m/sec)). As observed in the arms the 
nerves of the legs also presented a decline in the maximum conduction 
velocity proximally and distally in the age range of 40-65 yrs when compared 
to the age range of 15 to 30 yrs. This study clearly indicates that increase in 
age can induce decline in nerve conduction velocity. 
Another study done to assess the influence of age, height and BMI was 
done by Awang MS et al.99 The methodology included 250 healthy Malaysian 
subjects who were hospital staff and students with no evidence of 
neuromuscular or musculoskeletal diseases.The subjects were subdivided 
based on age, BMI and height. NCV test was done in all the subjects and,the 
nerves tested were Median, Ulnar, Common peroneal and sural nerves (both 
right and left). They observed slowing of NCVs with increasing BMI in the 
median nerve (both sensory and motor conduction). The NCV of the motor 
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conduction of the Ulnar nerve also showed a similar pattern as observed in the 
median nerve. Whereas, the sensory nerve conduction of the ulnar nerve did 
not show any changes. Slowing of nerve conduction velocity with increasing 
BMI was also observed for the common peroneal and sural nerve. The study 
showed that height did not affect the nerve conduction velocity,since they 
could not establish slowing of nerve conduction velocity across varying 
heights for the nerves they studied except for the common peroneal nerve. 
Thus they conclude the study by saying that age and BMI do have a definite 
impact on nerve conduction velocity. 
Though, several clinical studies have proved that increasing BMI and 
increasing age can slow down nerve conduction velocities in normal and 
hypertensive subjects, the molecular pathophysiology behind it has been least 
studied.We hypothesize and presume the following below said sequence of 
molecular pathophysiological events to occur in the control subjects that is 
aggravated by the presence of hypertension. 
BMI is an index of body’s visceral and abdominal fat overwhelming 
excessive fat in the body especially the abdominal fat which is an extreme and 
overwhelming source of free fatty acids, leading to the clinical state called 
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hyperlipidemia. Free fatty acids trigger the onset of oxidative stress in obese 
subjects and hypertensive subjects. 
Slowing of the nerve conduction velocity can occur by two main 
mechanisms.First, the mechanism that occurs as an outcome of demyelination 
is observed as latency changes in NCS recordings. The second phenomenon is 
by axonal degeneration observed as a decline in amplitude changes in NCV 
tests. Both these conditions are significantly affected by oxidative stress, a 
factor that commonly occurs with increasing BMI and age. Hypertension is 
perceived to aggravate the hypothesis,because of the onset of hyperlipidemia 
at an earlier stage with higher BMI in hypertension. 
A Study done by Brown et al100 was a national survey carried out to evaluate 
relationship between BMI, blood pressure, cholesterol,and  mean levels of 
HDL-C, hypertension and dyslipidemia. The national health and nutrition 
survey was carried out between 1988-1994, after adjusting for the crude age 
and age–specific means and proportions they analyzed multivariate odds ratio 
that quantified the association between hypertension, dyslipidemia and BMI. 
Their results established that more than one-half of the adult population were 
overweight (BMI 25 to 29.9) or obese (> or = 30). The prevalence of high 
blood pressure and mean levels of SBP and DBP increased as BMI increases 
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with ages that were below 60 years. Cholesterol levels also increases upto the 
BMI of 25,but did not rise beyond this. Rate of low HDL-Cholesterol 
increased and mean HDL-Cholesterol levels decreased as BMI increased. 
BMI, high blood pressure and abnormal lipids correlated when various factors 
were adjusted (age, race, education and smoking).The odds ratio were highest 
at the ages 20 to 39 but the trends were more apparent in the older ages. This 
study shows a significant correlation (p<0.001) between BMI, hypertension 
and abnormal lipids. 
5.1.12.3 BMI as an Index of Body fat percentage 
A cross-sectional study done by Ranasinghe et al101 proved that BMI is 
an index of Body fat percentage.The study included 114 participants, in the 
age range of 18-83 years which were grouped into 3 age groups; young 
age(18-39 yrs), middle age (40-59 yrs) and elderly (>60 yrs). Bioelectrical 
impedance analysis was used to calculate Body Fat % and also they calculated 
BMI correlation and regression analysis between age-BMI and age-Body Fat 
%. The correlation between BMI and BF% was at p<0.001. From this study 
the authors conclude that BMI strongly correlates with Body Fat % and age 
and gender significantly affects BMI-BF% (p<0.001).  
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5.1.12.4 Obesity mediated oxidative stress 
A study reported by Sankhlaet al102was designed to investigate the 
relationship of obesity with oxidative stress mainly mediated by increased 
abdominal adiposity and the study extended to assess the possible mechanism 
of metabolic syndrome induced by obesity. The study included 120 men and 
30 women, in the age range 17-26 yrs in both genders. Generalized and 
abdominal obesity was analyzed by measuring BMI and waist-to-hip ratio in 
all the subjects. They also studied blood glucose, lipid profile, serum 
malondialdehyde (MDA)( a product of lipid peroxidation usually measured in 
humans as an indicator of oxidative stress). They also measured serum 
adiponectin. Their results definitely showed that serum MDA levels with 
increasing BMI (as per the NIH classification). Normal weight subjects when 
compared with obese class-2 subjects who presented abdominal adiposity had 
a significantly (p<0.001) higher serum concentration of MDA; while obese 
subjects without abdominal adiposity (Class-I) presented non-significant 
difference in the levels of serum malondialdehyde levels when compared with 
normal subjects. Obese subject (Class I and Class II) even presented a 
statistically significant (p<0.001) difference in the malondialdehyde levels, 
thus predicting the importance of abdominal adiposity to the onset of 
oxidative stress. 
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5.1.12.5 Free Fatty acid Content and turnover determine the extent of 
oxidative stress in obese subjects 
Though abdominal obesity and hypertension link themselves through 
the resistance of insulin-mediated glucose disposal; abnormalities observed in 
the metabolism of non-esterified fatty acids are observed to play an greater 
role. A Study conducted by Egan et al103 with 17 abdominaly obese subjects 
(11 hypertensives, 6 normotensives) was to determine whether turnover and 
fatty acid concentration were related to blood pressure independent of 
hyperinsulinemia and resistance to Insulin mediated glucose disposal. During 
fasting and during euglycemichyperinsulinemia at 10 and 40 mU/ml/min, the 
following analyses were carried out such as glucose utilization, fatty acid 
concentration, and fatty acid turnover. The protocol was repeated with another 
30 subjects also who had a wide range of risk factors and also blood pressure 
data, glucose and fatty acid measurements during an insulin tolerance test. 
The 17 obese hypertensive subjects whose blood pressure was assessed 
correlated significantly (p<0.001) with the free fatty acid concentration and 
turnover but not with glucose disposal. The correlation remained statistically 
significant after insulin and index of sensitivity to insulin mediated glucose 
disposal were statistically controlled. The results suggest that blood pressure 
is related to the effects of insulin on fatty acid metabolism. The mechanism 
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suggest that insulin resistant hormone lipase increases blood pressure by 
increasing fatty acid concentration and turnover in hypertensivies. 
The elevated free fatty acid can induce elevation of blood pressure 
through oxidative stress which has been experimentally proved by a study 
done by Wang et al.104 The study assessed the possible mechanism of 
oxidative stress in the high free fatty acids (FFAs)-induced hypertension. The 
male Sprague-Dawley rat models were subdivided into three groups; Group 
I(Control),Group II(Free fatty acid group-induced by 4 hour infusion of 
intralipid and heparin),Group III(Supplemented N-acetyl cysteine antioxidant 
along with the intralipid and heparin infusion).  
Blood pressure measurements were recorded for all the rats, 
Endothelium dependent vasodilatation(EDV)/Endothelium independent 
vasodilatation was measured in an organ chamber. ROS levels (Reactive 
oxygen species), nitrotyrosine, GSH (Glutathione), NO2-/NO3- levels were 
measured in plasma. eNOS (Endothelial Nitric oxide synthase) mRNA was 
measured in endothelial cells by real time PCR. The results were as follows 
(i) Blood pressure was elevated in the Group II rats (FFA group following 4 
hour infusion of intralipid and heparin) and this was statistically significant 
(p<0.001) when compared to Group I (control). However group III 
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(Antioxidant supplemented group with intralipid and heparin infusion) did not 
show any changes in the levels of blood pressure. (ii) EDV in response to Ach 
was impaired (p<0.001) in Group II rats. Whereas, there was no significant 
changes observed in the Group III rats when compared to Group I control rats. 
(iii) Likewise NO2-/NO3-, Glutathione levels was significantly decreased 
(p<0.001) when compared to Group I and Group III  rats that presented no 
significant changes.This study shows that high free fatty acid levels induce 
oxidative stress that mediates potential destruction of nitric oxide causing 
imbalance between Angiotensin II and Nitric oxide causing the BP to deviate. 
Thus they suggest FFA plays an important role in causing elevation of BP 
through oxidative stress. 
It has already been discussed above that hypertension can induce 
subclinical axonal neuropathy and this might be caused by the prevailing 
hyperdyslipidemia that induces oxidative stress and oxidative stress converts 
nitric oxide to a more potent peroxynitrite that can trigger neuronal death via 
the activation of PARP(poly-ADP-ribose polymerase) enzyme.Oxidative 
stress can mediate demyelination. These processes cause amplitude and 
latency changes. Further clinical and experimental studies to prove this 
discussion are given below.   
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A clinical study by Kassemet al105shows that hypertriglyceridemia can 
induce peripheral neuropathy in neurologically asymptomatic patients. Their 
study recruited 24 patients (21 males and 3 females having triglyceride level 
above 300 mg/dl who had no neurologic complaints and no other causes of 
Peripheral neuropathy. These patients under went Nerve conduction studies. 
Their distal motor and sensory latencies (DL), motor or sensory conduction 
velocities (CV), and motor or sensory amplitudes were measured from the 
peroneal, posterior tibial, sural, median and ulnar nerves. Their results showed 
that 70.8% patients had a significant delay in the distal latency of the sural 
nerves, 66.7% significant delay in the distal latency of the sensory median 
fibers, 54.2% subjects showed a decrease in the motor conduction velocity of 
posterior tibial nerve and 33.3% patients presented a significant decrease in 
the sensory conduction velocity of the sural nerve. Amplitudes was not 
observed to be affected. The study concluded by saying that 
hypertriglyceridemia can affect conduction parameters in peripheral nerves 
which is suggestive of early peripheral neuropathy.  
Thus hypertriglyceridemia in hypertension mediates the onset of 
oxidative stress and is the prime culprit for nerve damage.  
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In hypertension there are not much clinical studies relating oxidative 
stress to peripheral nerve damage. However, studies which describe that 
antioxidant therapy can improve nerve conduction variables in diabetes has 
been proved and these are indirect studies that prove oxidative stress is main 
the factor in the destruction of the peripheral nerves.  
A study presented by Farvidet al106 is a double blind randomized 
placebo-controlled clinical study that was designed to assess if micronutrients 
supplementation could improve neuropathy indices. In their study 75 type 2 
diabetes patients were assigned to three treatment groups.They received single 
treatment for a period of 4 months as daily supplement. Group I or named as 
group MV received zinc (20 mg), magnesium (250 mg), vitamin C (200 mg) 
and E (100 mg). Group II or named as group MVB received the above 
minerals and vitamins along with vitamin B1 (10 mg), B6 (10 mg), biotin 
(200 mg) and folic acid (1 mg); Group III or named as Group P served as the 
placebo. Out of the 75 patients 67 patients completed the study. Neuropathic 
symptoms were derived based on MNSI questionnaire.Neuropathy symptoms 
improved from 3.45 to 0.64  ( p<0.001) in group MVB  from 3.96 to 1.0 
(p<0.001) in group MV and from 2.54 to 1.95 in placebo after the study 
period of 4 months. The clear outcome of this study is that micronutrient 
supplementation can improve diabetic neuropathy symptoms. 
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A study presented by Thiyagaranet al107 assessed the impact of lifestyle 
modification and lifestyle modification combined with yoga on BP and heart 
rate of individuals who presented with prehypertension (systolic BP 120-139 
mm Hg and/or diastolic BP 80-90 mm Hg). Volunteers were in the age range 
of 20-60 years of both genders without any known cardiovascular disease and 
were randomized to either LSM ( n= 92) or LSM + yoga group (n =92). Both 
the groups were assessed for age, waist circumference, physical activity, BP 
and fasting plasma glucose and lipids before and after the therapy. After 
therapy BP and Heart rate significantly reduced in both groups. Reduction 
was 6 mm Hg in the LSM + yoga group whereas 4 mm Hg in the LSM group. 
In addition 13 prehypertensives became normotensives in the LSM + yoga 
group, and 4 in LSM group. The study presented that aerobic exercise in any 
format can benefit in the reduction of BP and this is achieved by reducing the 
visceral and abdominal fat through these exercises. 
A Study presented by Tutuncu et al108 examined the effect of vitamin E, 
on electrophysiological parameters in patients with diabetic peripheral 
sensorymotor polyneuropathy.21 subjects with type 2 diabetes were enrolled 
for double-blind randomized placebo-controlled study (11 patients were 
supplemented vitamin E 900 mg for 6 months 11 patients served as placebo). 
Fasting glucose, HbAI, postprandial glucose and NCV parameter were 
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assessed at the basal state and after 6 months. Glycemic index did not show 
any significant changes during the study. However, nerve conduction in 2 of 
the 12 studied electrophysiological parameters showed improvement after 6 
months in patients treated with vitamin E. The changes were obvious in the 
median motor nerve fibers, and tibial motor nerve fibers. Nerve conduction 
velocity of the median nerve fiber (P = 0.0019) and tibial motor nerve distal 
latency (P < 0.0284) improved significantly after 6 months of vitamin E 
supplementation. This study proves that oxidative stress is a primary factor 
and it can improve nerve conductivity. 
An experimental study presented by Nagamatsuet al.109 determined 
whether lipoic acid could reduce oxidative stress in diabetic nerves and 
improve neuropathy. They used streptozotocin-induced diabetic neuropathy 
(SDN) rats and evaluated the efficacy of lipoic acid on nerve blood flow 
(NBF), electrophysiology and indexes of oxidative stress in peripheral nerves 
of rats is made diabetic with streptozotocin. At 1 month after onset of diabetes 
in age-matched control rats, lipoic acid was administered at the doses of 20, 
50 and 100 mg/kg intraperitoneally five times per week the onset of diabetes. 
The results showed a 50% reduction of nerve blood flow in the diabetic rats. 
Lipoic acid did not have effect on the nerve blood flow of normal nerves but 
improved in diabetic rats in a dose-dependent manner. After 1 month of 
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treatment with 100 mg of lipoic acid supplementation in the diabetic rats 
showed normal nerve blood flow, significant restoration of reduced 
glutathione when compared to SDN rats and alpha-tocopherol-deficient 
nerves.Conduction velocity of the digital nerve was reduced in diabetic rats 
that improved upon Lipoic acid supplementation. The study thus proved that 
lipoic acid improves the complications induced by diabetes by reducing the 
oxidative stress. Thus they suggest this drug may have potential effect in the 
treatment of human diabetic neuropathy. 
A Study presented by ReljanovicMet al110 was a prospective PLA-
controlled, randomized, double-blind study for a period of two years.Type 1 
and Type 2 diabetics were randomly assigned to three treatment regimens  
(i) 2 x 600 mg of TA (TA 1200 mg) 
(ii) 600 mg of TA and placebo (PLA)(TA 600 mg) 
(iii) Placebo and Placebo (PLA). 
A trometamol salt solution of TA of 1200 mg or 600 mg or PLA was 
intravenously administered once daily for five consecutive days, before 
enrolling the patients in oral treatment phase. The study carried out the 
following Neuropathy disability (NDS) score which measured the severity of 
the diabetic neuropathy. NCV of sural sensory nerve conduction velocity,and 
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the tibial (motor nerve conduction velocity, motor nerve distal latency were 
assessed.The final data analysis took consideration of 65 patients (TA 1200 
n=18, TA 600 n=27; PLA n= 20). At baseline there were no statistical 
differences observed in these groups. After 24 months statistical difference 
was observed between the TA and PLA for sural SNCV +3.8±4.2 m/s in TA 
1200, +3.0±0.3 m/s in TA 600, -0.1±-4.8 m/s in PLA(p<0.05 for TA 1200 and 
TA 600 vs PLA); sural SNAP +0.6±2.5 microV in TA 1200, +0.3/-1.4 
microV in TA 600, -0.7±15. microV in PLA (p= 0.075 for TA 1200 vs PLA 
and p<0.05 for TA 600 vs PLA), tibial MNCV ±1.2±3.8 m/s in TA 1200, -
0.3/-5.2 m/s in TA 600, 1.5±2.9 m/s in PLA (p<0.05 for TA 1200 vs PLA). 
No significant differences were observed between the groups after 24 months 
in the tibial motor nerve distal latency and NDS. In this study TA appeared to 
have a beneficial effect on several attributes of nerve conduction. 
A meta analysis study conducted by Rosenfeldt et al111 was to assess 
the efficacy of coenzyme Q10 for hypertension and to assess its overall 
efficacy and consistency of therapeutic action and side-effect incidence.12 
clinical trials were selected (362 patients) comprising three randomized 
controlled trials, one crossover trials (n=120), SBP in the treatment group was 
167.7 mm Hg and 151.1 mm Hg after a decrease of 16.6 mmg Hg (p<0.001), 
but there was no significant changes observed in the placebo group. DBP 
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presented an 8.2 mm Hg decrease(p<0.001) (103 mm Hg before treatment and 
94.8mm Hg after treatment) there was no significant changes observed in the 
placebo group. In the cross-over study (n=18), SBP decreased by 11 mm Hg 
and DBP by 8 mm Hg (p<0.001) with no significant change with placebo. In 
the open label studies ( n=214) mean SBP and DBP was 162 and 97.1 before 
treatment and it was observed to be 148.6 mm Hg and 86.8 mm Hg after 
treatment. SBP presented a decrease of 13.5 mm Hg and DBP presented a 
decrease of 10.3 mm Hg (p<0.001). Thus the study concluded that coenzyme 
Q10 has potential to lower SBP to 17 mm Hg and DBP to 10 mm Hg without 
significant side effects in the hypertensive patients.    
An experimental study presented by Sims-Robinson et al112 was to 
determine age-related deficits in the peripheral nervous system and the role of 
oxidative stress in this process. They used microarray technology to assess the 
functional and morphological changes in the normal wild-type mice and 
copper/zinc superoxide dismutase-deficient (Sod1(-/-)) mice, a mouse model 
of increased oxidative stress. Sod1(-/-) mice exhibited peripheral neuropathy 
phenotype with normal sensory nerve function and deficits in motor nerve 
function. Their data suggest that decrease in cholesterol synthesis that is vital 
to myelin formation, correlates with the structural deficits in axons, myelin 
and the cell body of motor neurons.Such deficits appeared after 30 months in 
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the Sod1(+/+) mice whereas in Sod 1 (-/-) mice it appeared at 20 months 
compared with mice at 2 months.The study demonstrated that the functional 
and morphological changes within the peripheral nervous system in the model 
of increased oxidative stress were manifested at an earlier age and resemble 
the deficits observed during normal aging.  
A study presented by Coppey LJ et al113 assessed the effect of 
antioxidant supplementation on diabetic rats vascular and neural function. 
They fed the diabetic rats either with 0.5% alpha-lipoic acid as diet 
supplement or hydroxyethyl starch deferoxamine (HES-DFO) by weekly 
intravenous injections at a dose of 75 mg/kg. The antioxidant treatment 
significantly improved diabetes induced decrease Endoneurial blood 
flow(EBF), acetylcholine-mediated vascular relaxation in arterioles and 
sciatic nerve motor nerve conduction velocity. The treatment also reduced the 
production ofsuperoxide content and peroxynitrite.Treating diabetic rats with 
alpha-lipoic acid prevented diabetes induced increase in thio-barbituric acid-
reactive substances and improved lens glutathione levels. But however, 
diabetes induced sciatic nerve conjugated diene levels were not restored by 
either alpha-lipoic acid or HES-DFO. Sciatic nerve Na+K+ATPase activity 
and myo-inositol levels was partially restored by alpha lipoic acid but not by 
HES-DFO. The authors perceive that diabetes-induced oxidative stress and 
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the generation of superoxide is partially responsible for the development of 
diabetic vascular and neural complications.  
A study conducted by Hernandez-Ojeda et al114 evaluated the oral 
impact of ubiquinone in diabetic polyneuropathy and the role of lipid 
peroxidation (LPO) and nerve growth factor (NGF-β). They conducted a 
double-blind placebo-controlled clinical trial.The patients were randomized to 
ubiquinone (400 mg) or placebo daily for 12 weeks. Main outcomes were 
clinical scores, NCV studies, LPO, NGF-β and safety assessment with the 
mean age of the 56 years, 22% males and 78% females, mean evolution of 
Type 2 diabetes was 10.7 years). Experimental group vs control group was 
found to show significant improvement in neuropathy symptoms score from 
2.5 +/- 0.7 to 1 +/- 0.8(p<0.001), neuropathy impairment score (5.5 +/- 4 to 
3.1 +/- 2.6 p<0.001), sural sensory nerve amplitude (13.0 +/- 6.1 to 15.8 +/- 
5.1 µV p = 0.049), peroneal motor nerve conduction velocity (39.7 +/- 5.0 to 
47.8 +/- 4.9 m/s p- 0.047) and ulnar motor nerve conduction velocity (48.8 +/- 
6.8 to 54.5 +/- 6.1 m/s, p= 0.046).  LPO reduced significantly in subjects 
treated with ubiquinone vs placebo (16.7 +/- 8.6 and 23.2 +/- 15.8 mmol/ml, 
respectively) with p<0.05 and NGF-β did not change; and no drug-related 
adverse reactions were reported in the study. This study reveals that 12 week 
ubiquinone therapy improved  clinical outcomes, nerve conduction 
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parameters by reducing oxidative stress in diabetic polyneuropathy patients 
without any adverse reactions. 
An experimental study done by Pacher et al115 was to evaluate reactive 
oxygen species triggered activation of nuclear enzyme Poly-ADP-ribose 
polymerase(PARP), which in turn contributes cardiac and vascular 
dysfunction in various diseases like hypertension,diabetesetc.Retired Breeder 
spontaneously hypertensive rats and apo E knockout mice were treated for 20 
weeks with PARP inhibitor PJ34. Treatment with PARP inhibitor did not 
influence blood pressure and cardiac hypertrophy in SHR(spontaneously 
hypertensive rats) but it did improve Ach-induced Nitric Oxide-mediated 
vascular relaxation. Thus it is known from this study that PARP activation 
leads to pathogenesis of endothelial dysfunction associated with hypertension 
and aging    
All these studies point to one common mechanism that can also be true 
in hypertension mediated peripheral nerve degeneration.The mechanism is 
that obesity and hypertension induce high levels of free fatty acids that in turn 
increase the levels of oxidative stress there by depleting nitric oxide and 
converting it to peroxynitrite, that in turn activates PARP to induce axonal 
degeneration. 
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Likewise oxidative stress could also cause demyelination process 
leading to the culmination of all these processes into peripheral neuropathy. 
Thus with this following mechanistic hypothesis this study was proceeded.  
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6.  Materials and Methods 
6.1 Study Design: 
 This study was designed as descriptive cross sectional study. 
6.2 Study Setting: 
 This study was conducted in the research laboratory in the Department 
of Physiology in Collaboration with Department of Medicine of 
SreeMookambika Institute of Medical 
Sciences,Kulasekharam,KanyakumariDistrict, Tamilnadu. 
6.3 Time of Study: 
 This study was done during the time period between April 2013 and 
July 2014 for over a period of 16 months. 
6.4  Sample size calculation: 
         The sample size of this study was determined based on the studies 
published in literature, which have shown that the prevalence rate of 
hypertensive neuropathy in hypertension is 25%. 
 The formula used is n = (Za + Zb)2 (P1Q1 + P2Q2)/(P1-P2)2 
Where Zα : z value for level of significance 
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 Zβ : z value for power of the test 
P1 : Proportion in sample 1 
Q1 : 100- P1 
P2 : Proportion in sample 2 
Q2 : 100-P2 
Zα : 1.98 for 5% level of significance  
Zβ : 0.86 for 80% power 
Hence by applying the formula 
n  = (1.98 + 0.86)2 (25 x 75) + (60 x 40)/ (25-60)2 
 = (8.1)(1875+2400)/ 35 x 35 
 =34627/1225 
 = 28.26 
6.5 Study groups:  
The study was planned to meet the aims and objectives by dividing the 
subjects into two groups (28 control subjects and 108 hypertensive subjects) 
after considering the inclusion and exclusion criteria. Each groups are further 
subdivided based on BMI and age.The detail of the study groups is given 
below in figure 5. 
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Figure 5:Description of the study groups 
 
  
Total 136 Subjects 
Control Group 28 Subjects Hypertensive group 108 subjects 
Divided based on Age & BMI 
Based on Age  
Group I   = Control subjects with age 30 – 45 yrs 
Group III = Control subjects with age 50 – 60 yrs 
Based on Mean BMI 
A = 19.5, B=26.75, C=31.5, D=35.6 
Divided based on Age & BMI 
Based on Age  
Group II  = Hypertensive subjects with age  30 – 45 yrs 
Group IV = Hypertensive subjects withy age 50-60 yrs 
Based on Mean BMI 
A = 19.5, B=26.75, C=31.5, D=35.6 
Group IA (Age 30-45yrs, BMI  19.5) 
Group IB (Age 30-45 yrs, BMI 26.75) 
Group IC (Age 30-45 yrs; BMI  31.5) 
Group ID (Age 30-45 yrs; BMI  35.6) 
Group IIIA (Age 50-60yrs, BMI  19.5) 
Group IIIB (Age 50-60 yrs, BMI 26.75) 
Group IIIC (Age 50-60 yrs; BMI  31.5) 
Group IIID (Age 50-60yrs; BMI  35.6) 
Group IIA (Age 50-60yrs, BMI  19.5) 
Group IIB (Age 50-60 yrs, BMI 26.75) 
Group IIC (Age 50-60 yrs; BMI  31.5) 
Group IID (Age 50-60yrs; BMI  35.6) 
Group IVA (Age 50-60yrs, BMI  19.5) 
Group IVB (Age 50-60 yrs, BMI 26.75) 
Group IVC (Age 50-60 yrs; BMI  31.5) 
Group IVD (Age 50-60yrs; BMI 3 5.65) 
60 
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Table 7: Grouping of the control volunteers and hypertensive patients based 
on age, BMI and Height. 
   Table 7a:  Control and hypertensive volunteers in the age range of 30-45, 
Mean BMI, and Mean Height 
 
Group 1A determines the Mean of Control subjects with age between 30-45 
years and Mean BMI 19.5 with a mean height 168.23  which is subdividedinto 
Group Ia (control subject with age 30 years with BMI 19.5 ± 0.26), Group Ib 
(control subject with age 35 years with BMI 19.5 ± 0.27),Group Ic (control subject 
with age 40 years with BMI 19.5 ± 0.25) and Group Id (control subject with age 45 
years with BMI 19.5 ± 0.28). N= Number of subjects in each group. 
Group II A (Mean of Hypertensive subjects with age between 30-45,Mean BMI 
19.5 and a Mean height 168.23) 
Grouping Age BMI Height 
Group II a (N = 3) 30 19.5 ± 0.26 168.23 ± 2.3 
Group II b (N = 3) 35 19.5 ± 0.27 168.23 ± 2.4 
Group II c (N = 3) 40 19.5 ± 0.25 168.23 ± 2.5 
Group II d (N = 3) 45 19.5 ± 0.28 168.23 ± 2.2 
 
Group 1 A (Mean of Control subjects with age between 30-45,Mean BMI 19.5 with a 
mean height 168.23) 
Grouping Age BMI Height 
Group I a (N =1) 30 19.5 ± 0.26 168.23 ± 2.3 
Group I b (N =1) 35 19.5 ± 0.27 168.23 ± 2.4 
Group I c (N =1) 40 19.5 ± 0.25 168.23 ± 2.5 
Group I d (N =1) 45 19.5 ± 0.28 168.23 ± 2.2 
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Group II A  determines the mean of Hypertensive subjects with age between 
30-45 years, Mean BMI 19.5 and a Mean height 168.23  which is subdivided into 
Group II a (Hypertensive subject with age 30  years with BMI 19.5 ± 0.26), Group 
II b(Hypertensive subject with age 35 years with BMI 19.5 ± 0.27),Group II c 
(Hypertensive subject with age 40 years with BMI 19.5 ± 0.25),Group II d 
(Hypertensive subject with age 45  years with BMI 19.5 ± 0.28). N= Number of 
patients in each group. 
 
 
 
 
 
 
Group I B determines the mean of control subjects with age between 30-
45years and mean BMI 26.75 and a mean height of 168.23.Group Ie (control 
subject with age 30 years with BMI 26.75± 0.26),Group If (control subject with 
age 35 years with BMI 26.75 ± 0.27),Group Ig (control subject with age 40 years 
with BMI 26.75± 0.25),Group Ih (control subject with age 45 years with BMI 
26.75 ± 0.28).N= Number of  subjects in each group. 
 
Group I B (Mean of control subjects with age between 30-45 Mean BMI 26.75 
and a mean height of 168.23) 
Grouping Age BMI Height 
Group I e (N =1) 30 26.75 ± 0.26 168.23 ± 2.3 
Group I f (N =1) 35 26.75 ± 0.27 168.23 ± 2.4 
Group I g (N =1) 40 26.75 ± 0.25 168.23 ± 2.5 
Group I h (N =1) 45 26.75 ± 0.28 168.23 ± 2.2 
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Group II B  determines the mean of Hypertensive subjects with age between 
30- 45 years, mean BMI 26.75 and a mean height of 168.23. Group II e 
(Hypertensive subject with age 30  years with BMI 26.75 ± 0.26, Group II f 
(Hypertensive subject with age 35  years with BMI 26.75 ± 0.27), Group II g 
(Hypertensive subject with age 40  years with BMI 26.75 ± 0.25), Group II h 
(Hypertensive subject with age 45  years with BMI 26.75 ± 0.2). N= Number of 
patients in each group. 
  
Group I C determines the mean of Control subjects with age between 30-45 
years,BMI 31.5 and a mean height of 168.23.Group I I (control subject with age 30 
years with BMI 31.5 ± 0.26),Group I j(control subject with age 35 years with BMI 
Group II B (Mean of Hypertensive subjects with age between 30-45  Mean BMI 26.75 
and a Mean height of 168.23) 
Grouping Age BMI Height 
Group II e (N =3) 30 26.75 ± 0.26 168.23 ± 2.3 
Group II f (N=3) 35 26.75 ± 0.27 168.23 ± 2.4 
Group II g (N =3) 40 26.75 ± 0.25 168.23 ± 2.5 
Group II h (N =3) 45 26.75 ± 0.28 168.23 ± 2.2 
Group I C ( Mean of Control subjects with age between 30-45 BMI 31.5 and a mean 
height of 168.23) 
Grouping Age BMI Height 
Group I i (N =1) 30 31.5 ± 0.26 168.23 ± 2.3 
Group I j (N =1) 35 31.5 ± 0.27 168.23 ± 2.4 
Group I k (N =1) 40 31.5 ± 0.25 168.23 ± 2.5 
Group I l (N =1) 45 31.5 ± 0.28 168.23 ± 2.2 
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31.5 ± 0.27),Group I k (control subject with age 40 years with BMI 31.5± 
0.25),Group I l (control subject with age 45 years with BMI 31.5 ± 0.28).N= 
Number of  subjects in each group. 
 
Group II C determines the mean of Hypertensive subjects with age between 
30-45years,BMI 31.5 and a mean height of 168.23 .Group II i (Hypertensive 
subject with age 30  years with BMI 31.5 ± 0.26),Group IIj (Hypertensive subject 
with age 35 years with BMI 31.5 ± 0.27),Group II k(Hypertensive subject with age 
40  years with BMI 31.5 ± 0.25),Group II l (Hypertensive subject with age 45  
years with BMI 31.5  ± 0.28.N= Number of  patients in each group. 
Group I D (Mean of Control volunteers with age between 30-45 Mean BMI 35.65 
and a Mean height 168.23) 
Grouping Age BMI Height 
Group I m (N =1) 30 35.65 ± 0.26 168.23 ± 2.3 
Group I n (N =1) 35 35.6 ± 0.27 168.23 ± 2.4 
Group I o (N =1) 40 35.6 ± 0.25 168.23 ± 2.5 
Group I p (N =1) 45 35.6 ± 0.28 168.23 ± 2.2 
Group II C (Mean of Hypertensive subjects with age between 30-45 BMI 31.5 and a 
mean height of 168.23) 
Grouping Age BMI Height 
Group II i (N =3) 30 31.5 ± 0.26 168.23 ± 2.3 
Group II j (N =3) 35 31.5 ± 0.27 168.23 ± 2.4 
Group II k (N =3) 40 31.5 ± 0.25 168.23 ± 2.5 
Group II l (N =3) 45 31.5 ± 0.28 168.23 ± 2.2 
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Group I D determines the mean of Control subjects with age between 30-45 
years ,mean BMI 35.65 and a Mean height 168.23. Group I m (control subject with 
age 30 years with BMI 35.65  ±  0.26), Group I n (control subject with age 35 
years with BMI  35.65±  0.27), Group I o (control subject with age 40 years with 
BMI  35.65 ±  0.25), Group I p (control subject with age 45 years with BMI  35.65 
±  0.28). N= Number of  subjects in each group. 
Group II D (Mean of Hypertensive subjects with age between 30-45 Mean BMI 
35.65 and a Mean height 168.23) 
Grouping Age BMI Height 
Group II m (N =3) 30 35.65 ± 0.26 168.23 ± 2.3 
Group II n (N =3) 35 35.6 ± 0.27 168.23 ± 2.4 
Group II o (N =3) 40 35.6 ± 0.25 168.23 ± 2.5 
Group II p (N =3) 45 35.6 ± 0.28 168.23 ± 2.2 
 
Group II D determines the mean of  Hypertensive  subjects with age between 
30-45 years and mean BMI 35.65 and a mean height 168.23. Group IIm 
(Hypertensive subject with age 30  years with BMI 35.6 ± 0.26), Group II 
n(Hypertensive subject with age 35  years with BMI 35.6 ± 0.27),Group II o 
(Hypertensive subject with age 40  years with BMI 35.6 ± 0.25), Group II p 
(Hypertensive subject with age 45  years with BMI 35.6  ± 0.28).N= Number 
ofpatients in each group.  
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     Table 7 b: Control and hypertensive subjects with age 50-60, mean BMI, 
and  Mean Height. 
Group III A (Mean of Control volunteers with age between 50-60 Mean BMI  19.5 and a 
Mean height 168.23) 
Grouping Age BMI Height 
Group III a (N =1) 50 19.5 ± 0.26 168.23 ± 2.3 
Group III b (N =1) 55 19.5 ± 0.27 168.23 ± 2.4 
Group III c (N =1) 60 19.5 ± 0.25 168.23 ± 2.5 
 
           Group III A  determines the mean of  Control subjects with  age between 
50-60 years, BMI mean 19.5 and a mean height 168.23. Group III a (control 
subject with age 50 years with BMI 19.5± 0.26), GroupIII b (control subject with 
age 55 years with BMI  19.5 ± 0.27), Group III c (control subject with age 60 years 
with BMI  19.5  ± 0.25). N= Number of  subjects in each group. 
Group IV A (Mean of Hypertensive subjects with age between 50-60 Mean 19.5 
and a Mean height 168.23) 
Grouping Age BMI Height 
Group IV a (N =4) 50 19.5 ± 0.26 168.23 ± 2.3 
Group IV b (N =5) 55 19.5 ± 0.27 168.23 ± 2.4 
Group IV c (N =6) 60 19.5 ± 0.25 168.23 ± 2.5 
 
Group IV A determines the mean of  Hypertensive  subjects with age 
between 50-60  years and mean BMI 19.5 and a mean height 168.23. Group IVa 
(Hypertensive subject with age 50  years with BMI 19.5 ± 0.26), Group IV b 
(Hypertensive subject with age 55  years with BMI 19.5 ± 0.27),Group IV  c 
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(Hypertensive subject with age 60  years with BMI 19.5 ± 0.25).N= Number of 
patients in each group. 
Group III B (Control volunteers with age between 50-60 BMI 26.75 and a Mean 
height 168.23) 
Grouping Age BMI Height 
Group III d(N =1) 50 26.75 ± 0.26 168.23 ± 2.3 
Group III e (N =1) 55 26.75 ± 0.27 168.23 ± 2.4 
Group III f (N =1) 60 26.75 ± 0.25 168.23 ± 2.5 
 
Group III B determines the Control subjects with age between 50-60 years 
,BMI 26.75 and a mean height 168.23. Group III d (control subject with age 50 
years with BMI 26.5 ± 0.26), Group III e (control subject with age 55 years with 
BMI  26.5 ± 0.27), Group III f (control subject with age 60 years with BMI  26.5 ± 
0.25). 
Group IV B (Mean of Hypertensive subjects with age between 50-60 BMI 26.75 
and a Mean of height of 168.23) 
Grouping Age BMI Height 
Group IV d (N=4) 50 26.75 ± 0.26 168.23 ± 2.3 
Group IV e (N=5) 55 26.75 ± 0.27 168.23 ± 2.4 
Group IV f (N=6) 60 26.75 ± 0.25 168.23 ± 2.5 
 
Group IV B determines the mean of Hypertensive subjects with age between 
50-60 years, BMI 26.75 and a Mean of height of 168.23.Group IV d (Hypertensive 
subjects with age 50 years with BMI 26.5± 0.26), GroupIV e (Hypertensive subject 
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with age 55 years with BMI 26.5 ±  0.27), Group IV f (Hypertensive subject with 
age 60 years with BMI 26.75 ± 0.25). N= Number of  patients in each group. 
Group III C (Control subjects with age between 50-60 Mean BMI 31.5 and a 
Mean height 168.23) 
Grouping Age BMI Height 
Group III g (N =1) 50 31.5 ± 0.26 168.23 ± 2.3 
Group III h (N =1) 55 31.5 ± 0.27 168.23 ± 2.4 
Group III i (N =1) 60 31.5 ± 0.25 168.23 ± 2.5 
Group III C determines the control subjects with age between 50-60 
years,mean BMI 31.5 and a mean height 168.23. Group III g (control subject with 
age 50 years with BMI 31.5± 0.26), GroupIII h (control subject with age 55 years 
with BMI  31.5± 0.27), Group III i (control subject with age 60 years with BMI  
31.5± 0.25) 
Group IV C (Mean of Hypertensive subjects with age between 50-60 Mean BMI 
31.5 and a Mean of height of 168.23) 
Grouping Age BMI Height 
Group IV g (N =4) 50 31.5 ± 0.26 168.23 ± 2.3 
Group IV h (N =5) 55 31.5 ± 0.27 168.23 ± 2.4 
Group IV i (N =6) 60 31.5 ± 0.25 168.23 ± 2.5 
Group IV C determines the mean of Hypertensive subjects with age between 
50-60 years mean BMI 31.5 and a mean of height of 168.23).Group IV g 
(Hypertensive subjects with age 50 years with BMI 31.5 ± 0.26), GroupIV h 
(Hypertensive subject with age 55 years with BMI  31.5 ± 0.27),Group IV 
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i(Hypertensive subject with age 60 years with BMI  31.5 ± 0.25).N= Number of  
patients in each group. 
Group III D (Mean of control subjects with age between 50-60 Mean BMI 35.65 
and a Mean of height of 168.23) 
Grouping Age BMI Height 
Group III j (N =1) 50 35.65 ± 0.26 168.23 ± 2.3 
Group III k (N =1) 55 35.65 ± 0.27 168.23 ± 2.4 
Group III l (N =1) 60 35.65 ± 0.25 168.23 ± 2.5 
Group III D  determines the mean of control subjects with age between 50-
60 years,mean BMI 35.65 and a mean height of 168.23.Group III j(control subject 
with age 50 years with BMI 35.6 ± 0.26),GroupIII k (control subject with age 55 
years with BMI  35.6 ± 0.27),Group III l (control subject with age 60 years with 
BMI  35.6 ± 0.25). 
Group IV D (Mean of Hypertensive subjects with age between 50-60 Mean BMI 
35.65 and a Mean of height of 168.23) 
Grouping Age BMI Height 
Group IV j (N =3) 50 35.65 ± 0.26 168.23 ± 2.3 
Group IV k (N =3) 55 35.65 ± 0.27 168.23 ± 2.4 
Group IV l (N =6) 60 35.65 ± 0.25 168.23 ± 2.5 
Group IV D determines the mean of Hypertensive subjects with age between 
50-60 years ,mean BMI 35.65 and mean height of 168.23.Group IV j(Hypertensive 
subjects with age 50 years with BMI 35.65± 0.26),GroupIV k(Hypertensive subject 
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with age 55 years with BMI  35.65± 0.27),Group IV l(Hypertensive subject with 
age 60 years with BMI  35.65± 0.25),N= Number of  patients in each group. 
6.6  Inclusion Criteria 
i)  Hypertension with SBP- 140-159 mm Hg, DBP- 90-99 mm of Hg with 
>10 years duration 
ii) Age between 30-60 years 
iii) Body mass index 18- 36 
6.7 Exclusion criteria 
1. History of Diabetes. 
2. History of peripheral vascular disease. 
3. Pregnancy. 
4. Alcohol abuse, Smoking, Tobacco users. 
5. Terminally ill hypertensive patients. 
6. History of Leprosy. 
7. Patients on other drugs which will impair/affect nerve conduction 
parameters like anticancer drugs, colchicine, ethambutol, lithium, phenytoin, 
isoniazid, leflunomide, dapsone, chloroquine, amiodarone etc. 
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8. Carpal tunnel syndrome 
9. End stage renal failure 
10. Stroke. 
11. Any medical disorders which impairs/affects nerve conduction parameters. 
12. Patients with h/o exposure to environmental toxins like lead, mercury, 
arsenic, thalium etc. 
6.8   Parameters: 
         Nerve conduction parameters like  
1. Duration,Latency(msec),conduction velocity (mtsec),amplitude (mv) of  motor 
peroneal nerve. 
2. Duration,Latency(msec),conduction velocity(mtsec),amplitide  (mv) of 
motor tibial nerve. 
3. Duration,Latency(msec), conduction velocity(mtsec),amplitude(mv) of 
sensory  sural  nerve. 
4. Duration,Latency(msec),conduction velocity(mtsec), amplitude (mv) of 
sensory  superficial peroneal  nerve. 
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6.9 Instrument used: 
The instrument used for this study was computerized RMS ALERON 401 
EMG/NCV/EP system designed for any neurophysiologic application.This 
machine includes nerve conduction study,needle electromyography(EMG), F 
Wave,H reflex and all evoked potentials.This was supplied by Recorders and 
Medicare system Pvt. Ltd.Chandigrah,India. 
6.10 Institutional Ethical Committee (IHEC) Approval: 
The study proposal was submitted to Institutional Human Ethical 
Committee(IHEC) of SreeMookambika Institute of Medical sciences (SMIMS) 
Kulasekharam (K.K.District),Tamilnadu for approval and the research proposal 
was approved by the Institutional Human Ethics committee(IHEC) of SMIMS with 
Ref. no. SMIMS/IHEC/2013/A/14.The certificate of approval for the same has 
been enclosed in annexure. 
6.11 Procedure 
6.11.1  Establishment of BMI: 
Volunteers’s height will be measured in barefoot to the nearest fraction of  
0.1cm by using wall fixed stadiometer. Body weight will be recorded to the nearest 
fraction of 0.1 kg by using a portable weighing machine. Subjects will be asked to 
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take off his/her shoes and jackets before weighing. Body Mass Index is calculated 
as the weight in kilograms divided by the square of the height in meters (kg/m2) 
using standard protocol. 
6.11.2  Establishment of Blood Pressure status: 
All control volunteers and hypertensive patients underwent blood pressure 
measurements.Standard mercury sphygmomanometer with appropriate cuff size 
was used to measure blood pressure. The subject was asked to sit relaxed in a chair 
with her/his arm supported comfortably and the pressure cuff was applied closely 
to the upper arm. The cuff was rapidly inflated to pressure above the level at which 
the radial pulse could no longer be felt. The stethoscope was placed lightly over the 
brachial artery and the mercury column was immediately allowed to fall at the rate 
of 2 mmHg per second. The first perception of the sound was taken as the systolic 
pressure and then the mercury was allowed to fall further till the sound ceased to 
be tapping in quality, became fully muffled, and finally disappeared. The level 
where it disappeared was taken as the diastolic pressure. The cuff was then 
deflated to zero pressure. The measurement was repeated twice with five-minute 
interval and the average taken for accuracy.      
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6.11.3 Nerve conduction study evaluation: 
 All subjects were investigated by a electrophysiological study of the motor  
tibial nerve, motor common peroneal nerve, sensory superficial peroneal nerve, 
sensory  sural nerve on both limbs by the RMS-EMG machine. 
All subjects were lying comfortably in supine position on an examination couch 
with the upper limb abducted 10-150 and flexed 100-150 at the elbow joint.  
6.11.4 MotorTibial nerve conduction procedure: 
Recording electrode/active electrode is placed on abductor hallicis or 
abductor digitiquinti,slightly below and anterior to navicular tuberosity.Reference 
electrode is placed distally to active electrode over the muscle tendon near the 
metatarsal head.Ground electrode is placed between the recording electrode and 
stimulation site (S1). 
Stimulation is given on both sites such as distal site and proximal site.The 
distal site stimulation is given behind and proximal to the medial malleolus (S1) as 
shown in Figure 6. 
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Figure 6: Pictorial representation of tibial nerve conduction study: 
Distal nerve stimulation. 
 
 
 
 
 
 
 
The proximal stimulation is given in the popliteal fossa,alongthe flexor crease of 
the knee (S2), slightly lateral to midline in popliteal fossa as shown in Figure 6. 
 From the stimulation sites,CMAPduration,latency,amplitude and conduction 
velocity are determined in the motor tibial nerve. 
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Figure 7: Pictorial representation of tibial nerve conduction study: Proximal  
nerve stimulation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.11.5  Motor common peroneal  nerve conduction procedure: 
Recording electrode /active electrode is placed on extensor 
digitorumbrevis.Reference electrode is placed distal to the active electrode over the 
muscle tendon.Ground electrode is placed between recording electrode and 
stimulation site. 
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Figure 8: Placement of electrodes and stimulation site for common peroneal  
nerve conduction study. 
 
Stimulation is given at ankle; 2cm distal to fibular neck, at the neck of fibula 
and 5-8 cm above the fibular neck for motor common peroneal nerve conduction 
study as shown in Figure 8 & 9.CMAP duration,amplitude,latency and conduction 
velocity are determined. 
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Figure 9: Pictorial representation of common peroneal  nerve conduction 
study. 
 
 
 
 
 
 
6.11.6 Sensory superficial peroneal  nerve conduction procedure: 
 Recording electrode /active electrode is placed just above the junction of 
lateral third of a line connecting the malleoli.Reference electrode is placed 3cm 
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distally to the active electrode.Ground electrode is placed between the recording 
electrode and stimulation site. 
Figure 10: Pictorial representation of sensory superficial  peroneal  nerve 
conduction study. 
 
 
 
 
 
 
 
 
 
 
Stimulation is given 10-15 cm proximal to upper edge of lateral malleolus 
anterior to peroneouslongus for sensory superficial peroneal nerve conduction 
study as shown in Figure 10.SNAP duration,amplitude, latency and conduction 
velocity are determined. 
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6.11.7 Sensorysural  nerve conduction procedure: 
             Recording electrode /active electrode is placed between lateral malleolus 
and tendoachilles.Ground electrode is placed between the recording electrode and 
stimulation site. 
Figure 11: Pictorial representation of sensory sural  nerve conduction study. 
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Stimulation is done antidromically 10-16 cm proximal to recording electrode 
distal to lower border of gastronemius at the junction of middle and lower third of 
leg as shown in Figure 11 
6.12 Statistical methods of analysis 
The data was entered into the Microsoft Office Excel 2007 for 
windows.GraphpadInstat version 3.06,32bit for windows was used to analyze the 
data.One way ANOVA followed by Bonferroni’s post hoc test was used to find the 
statistical significance between the groups. P<0.05 was considered as statistically 
significant. 
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7.  Results 
7.1 Study subjects: 
In this study, total of 136 subjects volunteered after considering the 
inclusion and exclusion criteria. They were divided into two groups which include, 
28 control subjects and 108 hypertensive patients. This grouping was further 
subdivided based on mean BMI and age.The  study was conducted with a mean 
height obtained from a range of heights of the study subjects. The baseline data 
with BMI calculation is given in Table 8.   
Table 8 : Basic data and BMI of Control and Hypertensive subjects for the age 
range of 30-60 years 
Age group 
(years) 
Mean Height 
(cm) 
Mean Body weight 
(kg) 
Mean BMI 
(m2/kg) 
30-60 168.23 ±  2.3 48.73 ± 1.8 19.5 ± 0.26 
30-60 168.23 ±  2.3 70.46 ± 2.5 26.75 ± 0.27 
30-60 168.23 ±  2.3 83.00 ± 3.6  31.5 ± 0.25 
30-60 168.23 ± 2.3 83.93 ± 4.2  35.65 ± 0.26 
 
Total no of subjects utilized for the basic data assessment N = 136 subjects 
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7.2  Blood Pressure Measurements 
Table 9a and 9b represents blood pressure measurements among the control 
and hypertensive subjects with varying mean BMI and age. 
The blood pressure changes among the study groups were statistically 
compared and the results are as follows.  
In the control subjects presented in table 8a and 8b; BMI and age did not 
show statistical significant changes in blood pressure measurements in the age 
group of 30-45 years. However, blood pressure measurements showed slightly 
significant changes to the statistical level of p<0.01 in Group III C (BMI 31.5, age 
50-60 years) and peak statistical significance of p< 0.001 in Group III D (BMI 
35.65, age 50-60 years). 
In the hypertensive subjects as presented table 8a and 8b,  BMI and Age 
showed statistically significant increase in blood pressure in Group II B (BMI 
26.75, age 30-45 years)(p<0.001). This statistical significance remained at p<0.001 
in all other BMI groups in the age range 30-45 and 50-60 years ; Group II C (BMI 
31.5, age 30-45 yrs), Group II D (BMI 35.65, age 30-45 yrs), Group IV A (BMI 
19.5, age 50-60 yrs), Group IV B (BMI 26.75, age 50-60 yrs), Group IV C (BMI 
31.5, age 50-60 yrs), Group IV D (BMI 35.65, age 50-60 yrs). 
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Table 9a: Blood Pressure measurements among control and hypertensivesin 
Age 30-45 years with Mean BMI and Mean Height 
Grouping  Systolic BP Diastolic BP 
Group I A 122.05 ± 0.06 80.38 ± 0.7 
Group II A 122.14 ± 0.01 
a* 
82.06 ± 0.22 
a* 
Group I B 122.07 ± 0.05 
bNS 
80.48 ± 0.55 
bNS 
Group II B 124.00 ± 0.01 
c***d*** 
84.08 ± 0.2 
c***d*** 
Group I C 122.09 ± 0.06 
eNS 
80.53 ± 0.54 
eNS 
Group II C 126.19 ± 0.01 
f***g*** 
86.09 ± 0.22  
f***g*** 
Group I D 122.10 ± 0.04 
hNS 
80.68 ± 0.46 
hNS 
Group II D 128.24 ± 0.01 
i***j*** 
88.09 ± 0.22 
i***j*** 
 
a = Group I A vs Group II A (BMI 19.5, age 30-45 yrs) 
b = Group I A vs Group I B (Grp I A- BMI 19.5, Grp I B- BMI 26.75, age 30-45 yrs)  
c = Group I B vs Group II B ( BMI 26.75, age 30-45 yrs) 
d = Group II A vs Group II B (Grp II A- BMI 19.5, Grp II B- BMI 26.75, age  30-45 yrs) 
e = Group I A vs Group I C ( Grp I A- BMI 19.5, Grp I C- BMI 31.5, age 30-45) 
f = Group I C vs Group II C (BMI 31.5, age 30-45 yrs) 
g = Group II A vs Group II C (Grp II A- BMI 19.5, Grp II C- BMI 31.5, age  30-45 yrs)  
h = Group I A vs Group I D (Grp I A –BMI 19.5, Group I D-35.65, age 30-45 yrs) 
i = Group I D vs Group II D (BMI 35.65, age 30-45 yrs)  
j = Group II A vs Group II D (Grp II A –BMI 19.5, Group II D-35.65, age 30-45 yrs) 
NS = Non significant,   *   =  p≤0.05,    ** =   p<0.01,   *** =   p<0.001 
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Table 9b: Blood Pressure among control and hypertensives in Age 50-60 yrs 
with Mean BMI and Mean Height 
Grouping  Systolic BP Diastolic BP 
Group III A 122.12 ± 0.05 80.5 ± 0.36 
Group IV A 128.24 ± 0.01 
a*** 
88.04 ± 0.25 
a*** 
Group III B 122.13 ± 0.06 
bNS 
80.60 ± 0.36 
bNS 
Group IV B 130.24 ± 0.01 
c***d*** 
90.18 ± 0.25 
c***d*** 
Group III C 122.37 ± 0.06 
e** 
82.1 ± 0.36 
e** 
Group IV C 132.55 ± 0.01 
f***g*** 
92.03 ± 0.25 
f***g*** 
Group III D 122.4 ± 0.06 
h*** 
82.20 ± 0.36 
h*** 
Group IV D 134.56 ± 0.01 
i***j*** 
98.03 ± 0.25 
i***j*** 
 
a = Group III A vs Group IV A (BMI 19.5, age 50-60 yrs) 
b = Group III A vs Group III B (Grp III A- BMI 19.5, Grp III B- BMI 26.75, age 50-60 yrs)  
c = Group III B vs Group IV B ( BMI 26.75, age 50-60 yrs) 
d = Group IV A vs Group IV B (Grp IV A- BMI 19.5, Grp IV B- BMI 26.75, age50-60 yrs) 
e = Group III A vs Group III C ( Grp III A- BMI 19.5, Grp III C- BMI 31.5, age 50-60 yrs) 
f = Group III C vs Group IV C (BMI 31.5, age 30-45 yrs) 
g = Group IV A vs Group IV C (Grp IV A- BMI 19.5, Grp IV C- BMI 31.5, age 50-60 yrs)  
h = Group III A vs Group III D (Grp III A –BMI 19.5, Group III D-35.65, age 50-60 yrs) 
i = Group III D vs Group IV D (BMI 35.65, age 50-60 yrs)  
j = Group IV A vs Group IV D (Grp IV A –BMI 19.5, Group IV D-35.65, age 50-60 yrs) 
NS = Non significant, * =  p≤0.05,   **  = p<0.01,     *** =  p<0.001 
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7.3  Nerve Conduction Study 
 Nerve Conduction studies were conducted for the lower proximities. Table 
9a and 9b represents the effect of BMI and age on tibial nerve conduction study 
variables in control and hypertensive subjects 
7.3.1  MotorTibial Nerve conduction variables: 
 From the Table 10a and 10b CMAP latency  and conduction velocities of 
tibial nerve in the control subjects starts to decrease significantly(p<0.05) from a 
BMI of 31.5 and age 30-45 years(Group I C), and statistical significance is also 
decreased with p<0.01 at BMI 35.65 and age 30-45 years(Group I D). CMAP 
latency and conduction velocity attain a significant statistical peak decrease of 
p<0.001 with a BMI of 19.5 and age 50-60 years(Group III A).  
This decreased statistical significance p<0.001 maintains with Increasing 
BMI and age of other Groups (Group III B (BMI 26.75), Group III C (BMI 31.5), 
Group III D (BMI 35.65), age 50-60 yrs. 
CMAP duration and Amplitude of tibial nerve of control subjects attains  
statistical significant decrease (p<0.05 ) at a BMI 35.65 in the age 30-45 years 
(Group I D).However duration and amplitude showed significance of p<0.01 at a 
BMI of 31.5 and 35.65 in Group IIIC and  IIID respectively in the age group of 50-
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60 years.In Group IIID (BMI 35.65)  showed statistical significance of p<0.001 in 
the age group of 50-60 years.  
    In the Hypertensive subjects, the onset of statistical peak significance 
(p<0.001) occurs in Group II D in BMI of 35.65 at a younger age range 30-45 yrs. 
Nerve conduction variables such as duration, amplitude, latency and conduction 
velocity attain peak statistical significance (p<0.001) at the same time in all other 
BMI groups of age 50-60 years. 
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Table 10a: Effect of hypertension on BMI on Motor Tibial Nerve conduction 
study variables in age group of 30-45 yrs 
GROUPING Motor 
Nerve 
CMAP Conduction 
Velocity Duration Amplitude Latency 
Group I A TIBIAL 6.40 ± 0.26 11.69  ± 0.5 10.18 ± 0.39 51.2 ± 0.15 
Group II A TIBIAL 
6.34 ± 0.22 
aNS 
11.56 + 0.16 
aNS 
10.16 + 0.35 
aNS 
50.6 + 0.15 
aNS 
Group I B TIBIAL 
6.25 ± 0.26 
bNS 
11.64 ± 0.15 
bNS 
10.18 ± 0.39 
bNS 
51.15 ± 0.16 
bNS 
Group II B TIBIAL 
5.60 ± 0.39 
c* 
11.59 ± 0.1 
cNS 
9.56 ± 0.15 
c*d* 
44.17 ± 0.18 
c*d*** 
Group I C TIBIAL 
6.13 ± 0.30 
eNS 
11.56 ± 0.20 
eNS 
9.73 ± 0.17 
e* 
50.98 ± 0.17 
e* 
Group II C TIBIAL 
5.73 ± 0.15 
f*g** 
11.39 ± 0.14 
fNSg* 
9.25 ± 0.25 
f**g** 
43.17 ± 0.18 
f***g*** 
Group I D TIBIAL 
6.09 + 0.29 
h* 
11.52 ± 0.13 
h* 
9.59 ± 0.32 
h* 
50.68 ± 0.17 
h** 
Group II D TIBIAL 
4.62 ± 0.26 
i***j*** 
10.00 ± 0.33 
i***j*** 
6.67 ± 0.65 
i***j*** 
40.86 ± 0.17  
i***j*** 
a = Group I A vs Group II A (BMI 19.5, age 30-45 yrs),  
b = Group I A vs Group I B (Grp I A- BMI 19.5, Grp I B- BMI 26.75, age 30-45 yrs)  
c = Group I B vs Group II B ( BMI 26.75, age 30-45 yrs) 
d = Group II A vs Group II B (Grp II A- BMI 19.5, Grp II B- BMI 26.75, age  30-45 yrs) 
e = Group I A vs Group I C ( Grp I A- BMI 19.5, Grp I C- BMI 31.5, age 30-45) 
f = Group I C vs Group II C (BMI 31.5, age 30-45 yrs) 
g = Group II A vs Group II C (Grp II A- BMI 19.5, Grp II C- BMI 31.5, age 30-45 yrs)  
h = Group I A vs Group I D (Grp I A –BMI 19.5, Group I D-35.65, age 30-45 yrs) 
i = Group I D vs Group II D (BMI 35.65, age 30-45 yrs)  
j = Group II A vs Group II D (Grp II A –BMI 19.5, Group II D-35.65, age 30-45 yrs) 
NS = Non significant,      * =  p≤0.05,**  =  p<0.01,       ***  =  p<0.001 
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Table 10b: Effect of hypertension on BMI on Motor Tibial Nerve conduction 
study variables in age group of 50-60 yrs 
GROUPING Motor 
Nerve 
CMAP Conduction 
Velocity Duration Amplitude Latency 
Group III A TIBIAL 6.01 ± 0.2 13.88 ± 0.15 9.68 ± 0.3 49.92 ± 0.3 
Group IV A TIBIAL 5.71 ± 0.15 a* 
13.3 ± 0.13 
a*** 
8.95 ± 0.4 
a** 
40.25 ± 0.13  
a*** 
Group III B TIBIAL 5.87 ± 0.25 b* 
13.51 ±  0.11 
b** 
9.58 ± 0.36 
b* 
48.92 + 0.16 
b*** 
Group IV B TIBIAL 4.61 ±  0.4 c*d** 
12.2 ± 0.14 
c***d*** 
7.25 ± 0.25 
c***d** 
39.25 ± 0.14  
c***d*** 
Group III C TIBIAL 5.71 ± 0.2 e** 
13.12 ± 0.10 
e*** 
9.18 ± 0.24 
e** 
47.92 ± 0.08 
e*** 
Group IV C TIBIAL 4.11 ± 0.3 f***g*** 
11.7 ± 0.16 
f***g*** 
6.75 ± 0.09 
f***g*** 
38.25 ± 0.13 
f***g*** 
Group III D TIBIAL 5.61 ± 0.25 h*** 
12.82 ± 0.15 
h*** 
8.68 ± 0.4 
h** 
46.92 ± 0.13 
h*** 
Group IV D TIBIAL 3.11 ± 0.2 i***j*** 
11.2 ± 0.14 
i***j*** 
5.25 ± 0.3 
i***j*** 
37.25 ± 0.13 
i***j*** 
 
 
a = Group III A vs Group IV A (BMI 19.5, age 50-60 yrs) 
b = Group III A vs Group III B (Grp III A- BMI 19.5, Grp III B- BMI 26.75, age 50-60 yrs)  
c = Group III B vs Group IV B ( BMI 26.75, age 50-60 yrs) 
d = Group IV A vs Group IV B (Grp IV A- BMI 19.5, Grp IV B- BMI 26.75, age50-60 yrs) 
e = Group III A vs Group III C ( Grp III A- BMI 19.5, Grp III C- BMI 31.5, age 50-60 yrs) 
f = Group III C vs Group IV C (BMI 31.5, age 30-45 yrs) 
g = Group IV A vs Group IV C (Grp IV A- BMI 19.5, Grp IV C- BMI 31.5, age 50-60 yrs)  
h = Group III A vs Group III D (Grp III A –BMI 19.5, Group III D-35.65, age 50-60 yrs) 
i = Group III D vs Group IV D (BMI 35.65, age 50-60 yrs)  
j = Group IV A vs Group IV D (Grp IV A –BMI 19.5, Group IV D-35.65, age 50-60 yrs) 
NS = Non significant,    *  =  p≤0.05,    **  =  p<0.01,     ***  =  p<0.001 
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7.3.2 Motor Common Peroneal Nerve conduction variables: 
Table 11a and 11b reflects the effects of BMI and age on common peroneal 
nerve conduction variables in control and hypertension subjects.  
In control subjects, Nerve conduction parameters such as CMAP Duration, 
Amplitude, latency and conduction velocity attains statistical significant decrease 
of p<0.1 at a BMI of 31.5 (Group I C age 30-45 yrs). This significant decrease 
sustains itself in the other Groups also; Group I D (BMI 35.65, age 30-45 yrs), 
Group III A (BMI 19.5, age 50-60 yrs). Also there is a statistical significance of 
p<0.01 in Group III B (BMI 26.75, age 50-60 yrs), Group III C (BMI 31.5, age 50-
60 yrs) Group III D (BMI 35.65, age 50-60 yrs) 
In Hypertensive subjects CMAP duration, amplitude, latency and conduction 
velocity attained statistically significant decrease in Group II B (BMI 26.75, age 
30-45 yrs) (p<0.1); CMAP duration, amplitude, latency and conduction velocity 
attains statistically significant peak decrease of p<0.001 in Group II D (BMI 35.65, 
age 30-45 years) and thereafter the statistical decrease maintained at the level of 
p<0.001 with increasing BMI and age groups, Group IV A (BMI 19.5, age 50-60 
years), Group IV B (BMI 26.75,age 50-60 yrs), Group IV C (BMI 31.5, age 50-60 
yrs), Group IV D (BMI 35.65, age 50-60 yrs) 
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Table 11a : Effect of hypertension on BMI on  Motor Common Peroneal 
Nerve conduction study variables in age group of 30-45 yrs 
GROUPING Motor Nerve 
CMAP Conduction 
Velocity Duration Amplitude Latency 
Group I A Common Peroneal 6..66 ± 0.26 3.97 ± 0.15 9.72 ± 0.39 51.12 ± 0.31 
Group II A Common Peroneal 
6.45 ± 0.24 
aNS 
3.22 ± 0.03 
aNS 
9.56 ± 0.37 
aNS 
50.97 ± 0.31 
aNS 
Group I B Common Peroneal 
6.46 ± 0.22 
bNS 
3.74 ± 0.15 
b* 
9.48 ± 0.31 
bNS 
50.87 ± 0.31 
bNS 
Group II B Common Peroneal 
6.08 ± 0.17 
c*d* 
3.66 ± 0.22 
cNSd** 
8.82 ± 0.32 
c*d* 
50.29 ± 0.26 
c*d** 
Group I C Common Peroneal 
6.23 ± 0.15 
e* 
3.50 ± 0.15 
e** 
9.01 ± 0.34 
e* 
50.72 ± 0.31 
e* 
Group II C Common Peroneal 
5.56 ± 0.26 
f**g** 
3.39 ± 0.15 
fNSg*** 
8.35 ± 0.17 
f**g*** 
49.87 ± 0.13 
f**g*** 
Group I D Common Peroneal 
6.20 ± 0.20 
h* 
3.48 ± 0.11 
h** 
8.99 ± 0.35 
h* 
50.69 ± 0.27 
h* 
Group II D Common Peroneal 
5.26 ± 0.24 
i***j*** 
2.92 ± 0.10 
i***j*** 
8.12 ± 0.17 
i***j*** 
49.87 ± 0.13 
i***j*** 
 
a = Group I A vs Group II A (BMI 19.5, age 30-45 yrs) 
b = Group I A vs Group I B (Grp I A- BMI 19.5, Grp I B- BMI 26.75, age 30-45 yrs)  
c = Group I B vs Group II B ( BMI 26.75, age 30-45 yrs) 
d = Group II A vs Group II B (Grp II A- BMI 19.5, Grp II B- BMI 26.75, age  30-45 yrs) 
e = Group I A vs Group I C ( Grp I A- BMI 19.5, Grp I C- BMI 31.5, age 30-45) 
f = Group I C vs Group II C (BMI 31.5, age 30-45 yrs) 
g = Group II A vs Group II C (Grp II A- BMI 19.5, Grp II C- BMI 31.5, age  30-45 yrs)  
h = Group I A vs Group I D (Grp I A –BMI 19.5, Group I D-35.65, age 30-45 yrs) 
i = Group I D vs Group II D (BMI 35.65, age 30-45 yrs)  
j = Group II A vs Group II D (Grp II A –BMI 19.5, Group II D-35.65, age 30-45 yrs) 
NS = Non significant,   *  =  p≤0.05,   **  =  p<0.01,    ***  =  p<0.001 
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Table 11b: Effect of hypertension on BMI on Motor Common Peroneal Nerve 
conduction study variables in age group of 50-60 yrs 
GROUPING Motor Nerve 
CMAP Conduction 
Velocity Duration Amplitude Latency 
Group III A Common peroneal 6.23 ± 0.15 3.36 ± 0.12 9.19 ± 0.3 50.33 ± 0.25 
Group IV A 
Common 
peroneal 
5.80 ± 0.2 
a* 
2.83 ± 0.12 
a** 
7.87 ± 0.4 
a** 
48.38 ± 0.10 
a*** 
Group III B 
Common 
peroneal 
6.08 ± 0.14 
b* 
3.21 ± 0.10 
b** 
7.62 ± 0.44 
b** 
49.47 ± 0.1 
b** 
Group IV B 
Common 
peroneal 
4.90 ± 0.25 
c***d** 
2.18 ± 0.13 
c***d** 
5.80 ± 0.20 
c***d*** 
46.00 ± 0.50 
c***d*** 
Group III C 
Common 
peroneal 
5.86 ± 0.10 
e** 
3.21 ± 0.12 
e*** 
7.09 ± 0.45 
e** 
49.30 ± 0.35 
e*** 
Group IV C 
Common 
peroneal 
4.71 ± 0.2 
f***g*** 
2.06 ± 0.07 
f***g*** 
3.88 ± 0.3 
f***g*** 
44.92 ± 0.8 
f***g*** 
Group III D 
Common 
peroneal 
5.56 ± 0.10 
h** 
3.06 ± 0.11 
h*** 
7.88 ± 0.3 
h** 
48.47 ± 0.1 
h*** 
Group IV D 
Common 
peroneal 
3.71 ± 0.2 
i***j*** 
1.4 ± 0.14 
i***j*** 
2.88 ± 0.4 
i***j*** 
43.92 ± 0.7 
i***j*** 
 
a = Group III A vs Group IV A (BMI 19.5, age 50-60 yrs) 
b = Group III A vs Group III B (Grp III A- BMI 19.5, Grp III B- BMI 26.75, age 50-60 yrs)  
c = Group III B vs Group IV B ( BMI 26.75, age 50-60 yrs) 
d = Group IV A vs Group IV B (Grp IV A- BMI 19.5, Grp IV B- BMI 26.75, age50-60 yrs) 
e = Group III A vs Group III C ( Grp III A- BMI 19.5, Grp III C- BMI 31.5, age 50-60 yrs) 
f = Group III C vs Group IV C (BMI 31.5, age 30-45 yrs) 
g = Group IV A vs Group IV C (Grp IV A- BMI 19.5, Grp IV C- BMI 31.5, age 50-60 yrs)  
h = Group III A vs Group III D (Grp III A –BMI 19.5, Group III D-35.65, age 50-60 yrs) 
i = Group III D vs Group IV D (BMI 35.65, age 50-60 yrs)  
j = Group IV A vs Group IV D (Grp IV A –BMI 19.5, Group IV D-35.65, age 50-60 yrs) 
NS = Non significant,     *  =  p≤0.05,    **  =  p<0.01,     ***   =  p<0.001 
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7.3.3  Sensory Superficial Peroneal Nerve conduction variables 
Table 12a and 12 b represents the effect of BMI and age on sensory 
superficial peronealnerve  in the control and hypertensive subjects. 
In control subjects SNAP duration, amplitude, latency and conduction 
velocity attains a statistical significant decrease of p<0.01 at a BMI of 31.5 in the 
age group of 30-45 years (Group I C). This significance of p<0.01 is sustained at a 
BMI of  35.65 in the age group of 30-45 years.(Group ID).The statistical 
significance reaches peak decrease  of p<0.001 in the Group III B (BMI 26.75, age 
50-60 yrs) which, is sustained in the other groups, Group III C (BMI 31.5, age 50-
60 yrs), Group III D (BMI 35.65 age 50-60 years). 
In the hypertensive group, SNAP duration, amplitude, latency, conduction 
velocity attained statistical significant decrease of p<0.01 at a lower BMI of 26.75 
in the age group of 30-45yrs (Group II B).This is in contrast to the control subjects 
where significant changes occur in a later BMI (Group I C). The statistical 
significance reaches peak decrease of p<0.001 at BMI 31.5 and BMI 35.65 in the 
age of 30-45 years.The statistical significance also reaches peak decrease of 
p<0.001 at a BMI of 26.75 (Group III B), 31.5(Group III C), 35.65 (Group III D) 
in the age group of 50-60 years. 
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Table 12a: Effect of hypertension on BMI on Sensory Superficial 
Peroneal Nerve conduction study variables in age group of  30-45 yrs 
GROUPING Sensory Nerve 
SNAP Conduction 
Velocity Duration Amplitude Latency 
Group I A 
Superficial 
Peroneal 0.289 ± 0.001 13.03 ± 0.095 10.97 ± 0.096  49.03 ± 0.10 
Group II A Superficial 
Peroneal 
0.288 ± 0.002 
aNS 
12.93 ± 0.094 
aNS 
10.89 ± 0.093 
aNS 
48.99 ± 0.090 
aNS 
Group I B 
Superficial 
Peroneal 
0.288 ± 0.001 
bNS 
12.94 ± 0.095 
bNS 
10.93 ± 0.095 
bNS 
48.97 ± 0.095 
bNS 
Group II B Superficial 
Peroneal 
0.280 ± 0.002 
c**d**  
12.63 ± 0.095 
c**d** 
10.68 ± 0.095 
c**d** 
48.625 ± 0.098 
c**d*** 
Group I C 
Superficial 
Peroneal 
0.283 ± 0.001 
e** 
12.73 ± 0.096 
e** 
10.675 ± 0.094 
e**  
48.73 ± 0.096 
e** 
Group II C 
Superficial 
Peroneal 
0.239 ± 0.002 
f***g*** 
11.73 ± 0.096 
f***g*** 
9.58 ± 0.093 
f***g***  
47.7 ± 0.094 
f***g*** 
Group I D Superficial 
Peroneal 
0.282 ± 0.001 
h** 
12.66 ± 0.094 
h** 
10.65 ± 0.094 
h** 
48.68 ± 0.08 
h** 
Group II D 
Superficial 
Peroneal 
0.209 ± 0.002 
i***j*** 
11.62 ± 0.095 
i***j*** 
9.53 ± 0.093 
i***j*** 
47.675 ±0.095 
i***j*** 
 
a = Group I A vs Group II A (BMI 19.5, age 30-45 yrs) 
b = Group I A vs Group I B (Grp I A- BMI 19.5, Grp I B- BMI 26.75, age 30-45 yrs)  
c = Group I B vs Group II B ( BMI 26.75, age 30-45 yrs) 
d = Group II A vs Group II B (Grp II A- BMI 19.5, Grp II B- BMI 26.75, age  30-45 yrs) 
e = Group I A vs Group I C ( Grp I A- BMI 19.5, Grp I C- BMI 31.5, age 30-45) 
f = Group I C vs Group II C (BMI 31.5, age 30-45 yrs) 
g = Group II A vs Group II C (Grp II A- BMI 19.5, Grp II C- BMI 31.5, age  30-45 yrs)  
h = Group I A vs Group I D (Grp I A –BMI 19.5, Group I D-35.65, age 30-45 yrs) 
i = Group I D vs Group II D (BMI 35.65, age 30-45 yrs)  
j = Group II A vs Group II D (Grp II A –BMI 19.5, Group II D-35.65, age 30-45 yrs) 
NS = Non significant,    *  =  p≤0.05,   **  =  p<0.01,   ***  =  p<0.001 
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Table 12b : Effect of hypertension on BMI on Sensory superficial Peroneal 
Nerve conduction study variables in age group of 50-60 yrs 
GROUPING 
Sensory 
Nerve 
SNAP Conduction 
Velocity Duration Amplitude Latency 
Group III A Superficial peroneal 0.28 ± 0.002 12.64 ± 0.1 10.6 ± 0.1 48.64 ± 0.1 
Group IV A 
Superficial 
peroneal 
0.198 ± 0.002 
a*** 
11.6 ± 0.1 
a*** 
9.44 ± 0.1 
a*** 
47.74 ± 0.3 
a*** 
Group III B Superficial peroneal 
0.25 ± 0.002 
b*** 
12.03 ± 0.1 
b*** 
9.7 ± 0.1 
b*** 
48.00 ± 0.2 
b*** 
Group IV B Superficial peroneal 
0.09 ± 0.002 
c***d*** 
10.00 ± 0.1 
c***d*** 
8.5 ± 0.1 
c***d*** 
47.00 ± 0.1 
c***d*** 
Group III C 
Superficial 
peroneal 
0.23 ± 0.001 
e*** 
11.8 ± 0.09 
e*** 
9.8 ± 0.08 
e*** 
47.8 ± 0.2 
e*** 
Group IV C Superficial peroneal 
0.08 ± 0.002 
f***g*** 
9.00 ± 0.08 
f***g*** 
8.00 ± 0.09 
f***g*** 
46.00 ± 0.3 
f***g*** 
Group III D 
Superficial 
peroneal 
0.22 ± 0.001 
h*** 
11.7 ± 0.2 
h*** 
9.7 ± 0.2 
h*** 
47.7 ± 0.1 
h*** 
Group IV D 
Superficial 
peroneal 
0.06 ± 0.002 
i***j*** 
7.00 ± 0.1 
i***j*** 
6.00 ± 0.1 
i***j*** 
44.00 ± 0.3 
i***j*** 
 
 
a = Group III A vs Group IV A (BMI 19.5, age 50-60 yrs) 
b = Group III A vs Group III B (Grp III A- BMI 19.5, Grp III B- BMI 26.75, age 50-60 yrs)  
c = Group III B vs Group IV B ( BMI 26.75, age 50-60 yrs) 
d = Group IV A vs Group IV B (Grp IV A- BMI 19.5, Grp IV B- BMI 26.75, age50-60 yrs) 
e = Group III A vs Group III C ( Grp III A- BMI 19.5, Grp III C- BMI 31.5, age 50-60 yrs) 
f = Group III C vs Group IV C (BMI 31.5, age 30-45 yrs) 
g = Group IV A vs Group IV C (Grp IV A- BMI 19.5, Grp IV C- BMI 31.5, age 50-60 yrs)  
h = Group III A vs Group III D (Grp III A –BMI 19.5, Group III D-35.65, age 50-60 yrs) 
i = Group III D vs Group IV D (BMI 35.65, age 50-60 yrs)  
j = Group IV A vs Group IV D (Grp IV A –BMI 19.5, Group IV D-35.65, age 50-60 yrs) 
NS = Non significant,   * = p≤0.05,   ** = p<0.01,    *** = p<0.001 
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7.3.4  Sensorysural nerve conduction variables. 
Table 13a and 13b represents the effect of BMI and age on sensory sural 
nerve in the control and hypertensive subjects. 
In the control subjects, SNAPduration, amplitude, latency and conduction 
velocity of sural nerve attains statistical significance p<0.001 in Group I C (BMI 
31.5, age 30-45 yrs) and this significance is sustained at a BMI of 35.65 in the age 
group of 30-45 years. This statistical significance is maintained with BMI 
19.5(Group III A), 26.75(Group III B),31.5(Group III C),36.5(Group III D) in the 
age group 50-60 years. 
          In the hypertensive subjects amplitude and latency attained statistical 
significance of p<0.01 and  duration as well as conduction velocity attained peak 
statistical significance in Group II B (BMI 26.75, age 30-45 years).However, 
SNAP duration, amplitude, conduction velocity attained peak statistical 
significance with p<0.001 in Group II C (BMI 31.5),Group II D(BMI 35.6) in age 
group 30-45 years and with BMI  19.5(Group IV A), 26.5(Group IV B),  
31.5(Group IV C),  35.6(Group IV D)  with age group 50-60 years.  
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Table 13a : Effect of hypertension on BMI on Sensory Sural Nerve conduction 
study variables in age group of 30-45 yrs 
GROUPING 
Sensory 
Nerve 
SNAP Conduction 
Velocity 
Duration Amplitude Latency 
Group I A Sural 0.539 ± 0.0009 15.77 ± 0.086 14.79 ± 0.087 33.29 ± 0.13 
Group II A 
Sural 0.538 ± 0.0008 
aNS 
15.72 ± 0.085 
aNS 
14.74 ± 0.086 
aNS 
33.19 ± 0.12 
aNS 
Group I B 
Sural 0.538 ± 0.0006 
bNS 
15.71 ± 0.084 
bNS 
14.69 ± 0.083 
b* 
33.19 ± 0.13 
bNS 
Group II B 
Sural 0.553 ± 0.0004 
c***d** 
15.47 ± 0.083 
c**d** 
14.47 ± 0.084 
c**d** 
32.86 ± 0.14 
c***d*** 
Group I C 
Sural 0.535 ± 0.007 
e*** 
15.27 ± 0.086 
e*** 
14.59 ± 0.083 
e*** 
33.09 ± 0.13 
e*** 
Group II C 
Sural 0.0529 ± 0.0005 
f***g*** 
14.87 ± 0.084 
f***g*** 
13.89 ± 0.084 
f***g*** 
32.69 ± 0.12 
f***g*** 
Group I D 
Sural 0.531 ± 0.0008 
h*** 
14.97 ± 0.082 
h*** 
14.29 ± 0.086  
h*** 
31.99 ± 0.13 
h*** 
Group II D 
Sural 0.519 ± 0.007 
i***j*** 
14.57 ± 0.085 
i***j*** 
13.79 ± 0.085 
i***j*** 
31.39 ± 0.11 
i***j*** 
 
a = Group I A vs Group II A (BMI 19.5, age 30-45 yrs) 
b = Group I A vs Group I B (Grp I A- BMI 19.5, Grp I B- BMI 26.75, age 30-45 yrs)  
c = Group I B vs Group II B ( BMI 26.75, age 30-45 yrs) 
d = Group II A vs Group II B (Grp II A- BMI 19.5, Grp II B- BMI 26.75, age  30-45 yrs) 
e = Group I A vs Group I C ( Grp I A- BMI 19.5, Grp I C- BMI 31.5, age 30-45) 
f = Group I C vs Group II C (BMI 31.5, age 30-45 yrs) 
g = Group II A vs Group II C (Grp II A- BMI 19.5, Grp II C- BMI 31.5, age  30-45 yrs)  
h = Group I A vs Group I D (Grp I A –BMI 19.5, Group I D-35.65, age 30-45 yrs) 
i = Group I D vs Group II D (BMI 31.5, age 30-45 yrs)  
j = Group II A vs Group II D (Grp II A –BMI 19.5, Group II D-35.65, age 30-45 yrs) 
NS = Non significant,   *  =  p≤0.05,   **  =  p<0.01,   ***  =  p<0.001 
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Table 13b : Effect of hypertension on BMI on Sensory Sural Nerve conduction 
study variables in age group of 50-60 yrs 
GROUPING 
Sensory 
Nerve 
SNAP Conduction 
Velocity Duration Amplitude Latency 
Group III A Sural 0.53 ± 0.0009  14.6 ± 0.09 13.87 ± 0.09  31.84 ± 0.10 
Group IV A Sural 0.50 ± 0.0007 a*** 
14.00 ± 0.09 
a*** 
13.17 ± 0.09 
a*** 
30.84 ± 0.10 
a*** 
Group III B 
Sural 0.51 ± 0.0008 
b*** 
13.8 ± 0.09 
b*** 
12.38 ± 0.09 
b*** 
31.14 ± 0.09 
b*** 
Group IV B Sural 0.48 ± 0.0009 c***d*** 
12.8 ± 0.09  
c***d*** 
12.27 ± 0.09 
c***d*** 
30.64 ± 0.10 
c***d*** 
Group III C Sural 0.492 ± 0.0009 e*** 
13.3 ± 0.07 
e*** 
11.87 ± 0.07 
e*** 
30.54 ± 0.08 
e*** 
Group IV C 
Sural 0.46 ± 0.0009 
f***g*** 
11.8 ± 0.09 
f***g*** 
11.77 ± 0.06 
f***g*** 
29.34 ± 0.1 
f***g*** 
Group III D 
Sural 0.47 ± 0.0008 
h*** 
12.8 ± 0.09 
h*** 
11.57 ± 0.05 
h*** 
30.14 ± 0.1 
h*** 
Group IV D 
Sural 0.44 ± 0.0008 
i***j*** 
10.8 ± 0.08 
i***j*** 
10.77 ± 0.09 
i***j*** 
28.34 ± 0.2 
i***j*** 
 
a = Group III A vs Group IV A (BMI 19.5, age 50-60 yrs) 
b = Group III A vs Group III B (Grp III A- BMI 19.5, Grp III B- BMI 26.75, age 50-60 yrs)  
c = Group III B vs Group IV B ( BMI 26.75, age 50-60 yrs) 
d = Group IV A vs Group IV B (Grp IV A- BMI 19.5, Grp IV B- BMI 26.75, age50-60 yrs) 
e = Group III A vs Group III C ( Grp III A- BMI 19.5, Grp III C- BMI 31.5, age 50-60 yrs) 
f = Group III C vs Group IV C (BMI 31.5, age 30-45 yrs) 
g = Group IV A vs Group IV C (Grp IV A- BMI 19.5, Grp IV C- BMI 31.5, age 50-60 yrs)  
h = Group III A vs Group III D (Grp III A –BMI 19.5, Group III D-35.65, age 50-60 yrs) 
i = Group III D vs Group IV D (BMI 35.65, age 50-60 yrs)  
j = Group IV A vs Group IV D (Grp IV A –BMI 19.5, Group IV D-35.65, age 50-60 yrs) 
NS = Non significant,   *  =  p≤0.05,   **  =  p<0.01,    ***  = p<0.001 
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8. Discussion  
The present study was done to assess the effect of hypertension on 
increasing BMI and age in nerve conduction study variables in patients 
attending the outpatient Department of General Medicine.The clinical 
procedures were conducted at the research laboratory in the Department of 
Physiology at SreeMookambika Institute of Medical Sciences located at 
Kulasekaram, Kanyakumari district. This study was designed to assess the 
effect of hypertension on BMI and age on nerve conduction variables since 
there are very few studies done to correlate hypertension with peripheral 
neuropathy, with age and BMI as aggravating factors. In India hypertension is 
the third leading killer under category of non-communicable disease.21 
8.1 BMI and Age: 
136 participants of the study were categorized into two main groups 
Control group and hypertensive group.This grouping was further subdivided 
into various groups based on BMI and age. Table 7 represents mean 
calculation of height and BMI in various age groups.Case History was 
recorded for all the 136 participants to verify the inclusion and exclusion 
criteria.The basic data such as height and weight were recorded from which 
the BMI was calculated. Mean Height and Mean BMI were standardized. One 
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single mean height was chosen for the entire study for all the group 
subdivisions. 
Mean BMI was divided into four major BMI’s falling in the normal 
range 19.5, Pre-obese 26.75,Obese Class I 31.5, Obese class II 36.5.This was 
achieved by following the classification of world health organization.116 The 
age grouping was subdivided into two ranges 30-45 yrs covering the younger 
subjects, and 50-60 yrs covering the elderly subjects. 
8.2 Blood Pressure: 
Table 9a and 9b represents the blood pressure measurements in the age 
range 30-45 yrs and 50-60 yrs, mean BMI in both control subjects and 
hypertensive patients. In the control subjects there was significant statistical 
increase in the levels only in the age range of 50-60 yrs in the obese class I 
(Group III C), and Obese Class II (Group III D). 
This is in contrast with the hypertension subjects where significant 
changes in blood pressure occurs in the normal range BMI of 19.5 in age 30-
45 yrs and the statistical peak significance occurs in Class II Obese (Group II 
D) in the range of 30-45 yrs. 
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8.3 Nerve conduction studies: 
To assess the effect of hypertension on nerve conduction study 
variables along with BMI and age as co-factors; two motor nerves (Tibial and 
Common peroneal nerve) and two sensory nerves (Superficial peroneal and 
sural nerve) were studied in the control and hypertensive subjects. 
Table 10a and 10b represents the variables of Tibial nerve conduction 
studies such as duration,latency,conduction velocity. Here the onset of 
statistical peak significance appears to occur in the Obese class I (Group III 
C) in the age range of 50-60 yrs.     
Whereas,amplitude showed statistical significance which reaches the 
peak value in the control subjects only in the Group III D (Obese Class I) in 
the age range of 50-60 yrs. 
These values are significant in contrast with the hypertension group in 
which changes in duration,Latency and conduction velocity appear to show 
peak statistical significance in the Obese Class II (Group II D) in the age 
range of 30-45 years. This is an earlier onset,when compared to the control 
subjects.  
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The amplitude changes also appear to occur in an earlier age range of 
30-45 years,in the hypertensive subjects occurring in Group III D (Obese 
Class II). 
Table 11 a and 11 b represent the nerve conduction variables occurring 
in the motor common peroneal nerve. The statistical trend of the motor 
common peroneal nerve conduction variables were similar and identical to the 
statistical trend of the motor tibial nerve, in which the onset of changes in 
nerve conduction study variables occurred at a later age (50-60 years) in the 
control group. The duration,latency and conduction velocity shows peak 
statistical significance in the above said age range in obese class I (Group III 
C). Whereas, the amplitude changes occur only in the obese class II (Group 
III D). 
In the hypertensive subjects changes in duration,amplitude,latency and 
conduction velocity occur relatively at a younger age range of 30-45 yrs; 
obese class II (Group II D). 
Table 12a and 12b represent the nerve conduction variables of sensory 
superficial peroneal nerve. The trend of statistical significance is similar when 
compared to the motor nerves in which changes occur in later age range (50-
  Discussion 
103 
 
60 years) in control group; whereas; in an earlier age in the hypertensive 
group (30-45 years).  
Duration, amplitude, latency and conduction velocity showed statistical 
significance in Pre-obese state in the age range of 50-60 yrs (Group III C) in 
the control subjects. 
Whereas, in Hypertension subjects, changes are observed in the obese 
class II (35.65) in the age range 30-45 years (Group II D). 
Table 13a and 13b represent the nerve conduction variables of sensory 
sural nerve. Statistical significant changes in the sensory sural nerve occurred 
in the age range of 30-45 years,but the onset BMI was different in control and 
hypertensive subjects. 
The BMI was obese class II (35.65) in control subjects (Group I D); 
whereas, in the hypertensive’s the BMI was in the Pre-Obese (26.75)(Group 
II D) with age 30-45 years. The significant changes appeared in all the nerve 
conduction variables such as duration, amplitude, latency and conduction 
velocity in both the groups.  
Though certain papers report a negative association between 
hypertension and peripheral neuropathy96,97. Our study presents a positive 
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correlation  between hypertension and peripheral neuropathy. However, there 
are studies that present a positive correlation between hypertension and nerve 
conduction studies by Dhafir. I El-Yassinet. al.51  BMI and age related studies 
done by Awang et al99 observed that with increasing BMI and age in control 
subjects there is slowing of nerve conduction velocity in median (both motor 
and sensory) nerve with increasing BMI and age. 
Another study published in the Indian J. PhysiolPharmacol in 2012 by 
Pawar SM et al.117 has also similar findings related to our study. They report 
prolongation of distal motor latency with increasing BMI. They also observed 
F-wave minimum velocity which was significantly prolonged in motor tibial 
nerve  
Dhafir I. El- Yassin51 has clinically proved a positive correlation 
between hypertension and nerve conduction velocity and reports that patients 
with hypertension present peripheral sensory neuropathy mainly of axonal 
type with demyelination as an secondary outcome only in the sural nerve. 
In our study demyelination and axonal changes observed as alterations 
in the nerve conduction study variables such as CMAP or SNAP latency and 
amplitude changes in hypertension the changes occurring at a relatively 
earlier age range 30-45 years in the obese class I (BMI 26.75) in the control 
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subjects the changes in the same age range 30-45 years at a higher range. 
These results are in agreement with Dhafir I. El- Yassin’s paper.51 
8.4 Molecular Pathophysiology Pertaining To Nerve Conduction 
Variables 
Though we have a clear understanding that BMI and age can cause 
deficits in nerve conduction variables in control subjects; the presence of 
hypertension in a subject along the with age and BMI as co-factors could 
aggravate the deficits in nerve conduction variables at an earlier age when 
compared to control subjects thus making them prone to present with 
peripheral neuropathy. 
Though our study has not included much pathophysiology experiments 
we were interested in finding a basic working molecular pathophysiologic 
mechanism that would enlighten us on what is the process of BMI and age in 
reducing the nerve conduction variables. 
We hypothesize that hypertension mediated dyslipidemia can cause 
oxidative stress that in turn imbalances Angiotensin II and vasodialator 
balance especially nitric oxide and endothelin-1. The process is continued as a 
feed forward mechanism since the antioxidant status is compromised due to 
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oxidative damage to the antioxidant enzymes and the presence of high volume 
of free radicals being the primary culprits of oxidative stress. 
Depletion of Nitric oxide is an outcome of oxidative stress which 
mediates the production of peroxynitrite a biological reaction of nitric oxide 
with single oxygen (free radical). The formation of peroxynitrite and free 
radicals and depletion of antioxidants mediate the activation of aging 
mechanisms such as senescence and apoptosis that culminate into axonal 
degeneration observed as CMAP or SNAP amplitude decrease with 
prolongation of duration in control and hypertensive subjects that occurs at 
earlier stage in the hypertensive subjects. This is possibly due to onset of 
oxidative stress at an earlier stage and its non-depletion,despite various 
therapies targeted at hypertension. 
Axonal degeneration or apoptosis of the nerve occurs as an outcome of 
oxidative stress mediated by Poly-ADP-ribose polymerase [PARP], an death 
enzyme present within the Axon. 
Demyelination is an outcome of degeneration of myelin which is also 
achieved by oxidative stress implementing uncontrolled and irreversible lipid 
peroxidation causing the degradation of  myelin which causes latency changes 
in the nerve conduction. 
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Finally the Na+K+ATPase at the nodes of Ranvier 0 also lose 
functionality due to deprivation of ATP that is an outcome of inefficient 
mitochondrial functioning during the onset of Axonal degeneration. 
All these processes finally culminate into functionally defective nerve, 
incapable of firing; and is witnessed clinically as peripheral neuropathy in the 
peripheral nerves in hypertension. 
Crowley SD 118 and Yasunari K et al119 have proved clinically that 
oxidative stress is an outcome of chronic inflammation in hypertensive 
subjects. The onset of oxidative stress in hypertensive subjects depletes the 
levels of nitric oxide via the formation of peroxynitrite. This mechanism has 
been clinically proved by Moriel P et al120.  
Peroxynitrite mediated activation of PARP has been experimentally 
been proved in spontaneously hypertensive rats by Dereset al.121. The 
association of PARP activity mediating axonal degeneration has been 
experimentally proved in a rat model of multiple sclerosis by Penberty WT 
and Tsunoda I122; and the presence of axonal degeneration in hypertension has 
been proved experimentally in SHR rats by Sanada LS et al123. SHR rats are 
molecular mimics of essential hypertension and they serve as good 
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counterparts in working the mechanisms behind essential hypertension that 
cannot be done in human subjects. 
Demyelination has also been proved both clinically as latency changes 
in control subjects by Awanget al99, and experimentally by Sanada LS et al123 
Our study clearly demonstrates, axonal degeneration as changes in 
CMAP or SNAP amplitude and prolongation in duration in control subjects 
with higher BMI and age; whereas, in the essential hypertensives changes 
occurred in lower age range with increasing BMI. 
Demyelination was also observed as latency changes in our study 
following the same trend of onset in control and hypertensive subjects as 
indicated for axonal degeneration. 
Our findings are supported by clinical studies of Henry C. et al124, who 
has studied the effect of aging on sensory nerve conduction parameters and 
has presented that sensory nerve conduction velocity does change with aging.  
Aging mechanisms have experimentally proved in hypertension by                
Kung CF et al125 
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Demyelination is observed as latency changes with increasing BMI and 
age which has been clinically proved by Awanget al99 and experimentally it 
has been proved by Sanada LS et al123 
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9. Conclusion 
Hypertension enhanced the effect of BMI and age included increased 
blood pressure and slowing of nerve conduction variables. 
Increasing BMI and age caused increased blood pressure and nerve 
conduction variables in the control subjects. 
These effects were significantly increased in the hypertension with 
increasing BMI and age. Since the onset age of these variables occurred at an 
younger age. 
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10.Summary 
Sensation, pain, and voluntary movements are very essential. These are 
molecularly controlled by the peripheral nerves. 
In the present scenario urbanization is surplusly increasing in the 
percentile of non-communicable diseases. Especially diseases such as 
diabetes, hypertension, Obesity are perceived to cause deterioration in the 
peripheral nerves. This deterioration in the peripheral nerves is enhanced by 
BMI and age. The extent of deterioration has been well demonstrated in 
diabetes due to the high prevalence of diabetic foot. 
But peripheral neuropathy is perceived to appear in hypertension but is 
an area very less worked and persists with a conflict of interest with certain 
authors acknowledging that hypertension can cause peripheral neuropathy 
while others perceive that hypertension could not cause such changes. 
So our study was aimed to analyze whether hypertension caused nerve 
conduction variables deterioration and whether this could be enhanced by 
BMI and age. 
This was a comparative descriptive study conducted with 136 subjects 
who were grouped into Group (n=27) normal subjects and Group II (n=108). 
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Both the groups were subdivided based on age, 30-35 yrs constituted the 
younger age group and 50-60 yrs constituted the older age group. Both age 
groups were further divided based on the BMI into four classes following the 
NIH classification. Into Normal (19.5 BMI), Obese class I (26.75BMI), Obese 
Class II   (31.5 BMI), Obese Class III (36.5 BMI). 
Basic data such as height and weight age and sex were recorded and the 
case history was studied BMI was calculated and blood pressure was 
measured using sphygmomanometer and nerve conduction variables of the 
tibial nerve, motor common peroneal nerve, superficial peroneal nerve and 
sensory sural nerve was recorded using RMS-EMG instrument supplied from  
Recorders and Medicare system Pvt. Ltd.Chandigrah,India. 
The results analyzed showed that with increasing BMI significant blood 
pressure changes were caused along with increasing age and hypertension 
significantly increased changes making the changes making the changes at an 
earlier age. 
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CASE RECORD FORM 
Study Title : Effect of hypertension on nerve conduction parameters in patients 
attending Sree Mookambika Institute of  Medical Sciences, Kulasekharam. 
Serial No:         Date :  
Name : 
Age:  
Sex : 
Address: 
Occupation : 
Contact No: 
Hospital Reference No: 
History of Hypertension: 
Any other relevant history/ information: 
General examination: 
Height in (cm)  :  
Weight in (kg)  : 
BMI (Body mass index) : 
Heart rate (per minute) : 
 BP  (mm of Hg): 
Systemic Examination: 
Examination of central nervous system:  
                   a)Examination of higher functions: 
                   b)Examination of sensory system: 
                   c)Examination of motor system: 
                   d)Examination of reflexes: 
                  e)Examination of cranial nerves: 
Examination of other systems: 
Blood pressure Measurement: 
                   Systolic Bp(mm of Hg): 
                   Diastolic Bp(mm of Hg): 
Electrophysiological Investigations: 
Nerve Latency(millisec) Amplitude 
(millivolt) 
Conduction 
velocity 
(mt sec) 
 
     Duration 
 Right Left  Right Left Right Left Right Left 
Sural 
(sensory) 
        
Tibial 
(motor) 
        
Peroneal 
(sensory) 
        
Peroneal 
(motor) 
        
 
 
ABBREVATIONS 
AGE Advanced Glycation End products 
ANOVA Analysis of Variance 
BMI Body Mass Index 
CMAP Compound MuscleAction Potential 
CI Confidence interval 
DNA Deoxyribo Nucleic Acid  
EBF Endothelial Blood Flow 
HES HydroxyethylStrachDeferoxamine 
IGF Insulin Growth Factor 
JNC Joint National Committee 
LPO Lipid Peroxidation 
MDA Malondialdehyde 
NAP Nerve Action Potential 
NGF Nerve Growth Factor 
NT3 Neurotrophin- 3 
NCS Nerve Conduction Velocity 
NBF Nerve Blood Flow 
NCV Nerve Conduction Velocity 
OR Odds Ratio 
PARP Poly ADP Ribose Pathway 
PNS Peripheral Nervous System 
PKC Phosphokinase C 
ROS Reactive Oxygen Species 
SDN Strepotozotocin induced diabetic neuropathy 
SHR Spontaneously Hypertensive Rats 
SNAP Sensory Nerve Action Potential 
TERT Telomerase Reverse Transcriptase 
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INFORMATION FOR PARTICIPANTS OF THE STUDY 
 
 
 
 
 
 
 
1. Name of the principal  Investigator : Dr. L. Aswathy 
                                      Post Graduate 
                                      Dept of Physiology 
                                     SMIMS, Kulasekharam. 
 
2. Name of the guide :  Dr. M. S. Kumari Sheela (M.D) 
            Professor and Head 
            Department of Physiology 
           SMIMS, Kulasekharam. 
 
3. Name of the Co-guide : Dr. J. Kaniraj Peter (M.D) 
            Professor and Head 
           Department of Medicine 
          SMIMS, Kulasekharam. 
 
4. Institute : Sree Mookambika Institute of Medical Sciences (SMIMS) 
              Kulasekharam, Kanyakumari District, Tamilnadu.                                                                                                
 
5. Title of the Study : 
 Effect of Hypertension on Nerve conduction parameters in patients attending 
Sree     Mookambika Institute of Medical Sciences,Kulasekharam. 
Dear Volunteers, 
 We welcome you and thank you for your keen interest in participation in this 
research project. Before you participate in this study, it is important for you to 
understand why this research is being carried out. This form will provide you all the 
relevant details of this research. It will explain the nature, the purpose, the benefits, the 
risks, the discomforts, the precautions and the information about how this project will be 
carried out. It is important that you read and understand the contents of the form 
carefully. This form may contain certain scientific terms and hence, if you have any 
doubts or if you want more information, you are free to ask the study personnel or the 
contact person mentioned below before you give your consent and also at any time 
during the entire course of the project. 
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6. Background Information: 
The most important medical and public health issue and the single cause of 
death world wide is high blood pressure.The death occurs through heart attack, stroke 
and kidney disease. 
The situation in India is graver, since with mordernization, we are trading 
healthy traditional diets for fatty foods, physical jobs for desk bound ones and calm 
rural life for stressful city life. India is slated to become the hypertension capital next to 
diabetic capital. There is also a rapid increase in the incidence and consequent 
prevalence of hypertension. So it is important to have a reliable information about the 
prevalence of Hypertension in different world regions for the development of national 
& International Health Policies for prevention and control of this condition.The 
increased risks are present in individuals ranging from 40- 89 years of age. Due to 
technological advances, there is dramatic change in life style of people and overall 
prevalence of Hypertension (JNL-VI) in South India is 12.5%. 
In 95% of cases essential hypertension may precede the onset of 
diabetes.Hypertension is defined as sustained elevation of BP ≥ 140/90 mm of Hg. It is 
easy to diagnose, simple to treat and availability of drugs is present, but sometimes it 
remains undetected, untreated and sometimes treatment may not be adequately 
effective. 
Nerve conduction study is an essential study in the diagnosis of peripheral 
neuropathies. It has become a reliable test in clinical settings for diagnosing diseases of 
peripheral nerves. 
The constituent of electrophysiology and electrophysiological tests is nerve 
conduction or electroneurography. They are reliable and provide reproducible 
approaches to detection and characterization of nerve, muscle, neuromuscular junction 
diseases. Nerve conduction study consist of non invasive electrical stimulation of 
peripheral nerve at one site and non invasive measurement of evoked response at 
second site in the nerve (sensory or mixed nerve conduction) or over the muscle 
innervated by the nerve (motor nerve conduction)  
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Nerve conduction study measures duration,latency,amplitude and conduction 
velocity. Conduction velocity and latency denote the speed of nerve impulse 
propogation. They are altered in disease which cause demyelination. Amplitude denote 
the number of functioning fibres and it is altered in diseases causing axonal 
degeneration. 
The world health theme according to WHO for the year 2013 is High blood 
pressure. The ultimate goal is to create greater awareness, healthy behaviour improved 
detection and enabling enviornment. 
Inspite of thorough review it was found that several nerve conduction studies 
are done among normal individuals. There are very few studies across the world in 
nerve conduction study among hypertensives. Hence there is a need to look into these 
parameters particularly among rural population.   
7. Aims and objectives: 
1. To assess the effect of hypertension in nerve conduction Parameters. 
2.To study the association of age and Body mass index on nerve conduction 
parameters in hypertensives. 
8.. Scientific justification of the study: 
Inspite of thorough review it was found that several nerve conduction 
studies are done among normal individuals. A study done on nerve conduction in 
healthy individual a premilinary age based study showed that age has definite 
effect on amplitude and duration of motor & sensory nerves. Another study done 
on body mass index on nerve conduction parameters showed that body mass 
index affect nerve conduction parameters.There are very few studies across the 
world in nerve conduction study among hypertensives. Hence there is a need to 
look into these parameters on hypertensives so that people can be made aware of 
the complications due to hypertension.  
The world health theme according to WHO for the year 2013 is high 
blood pressure. The ultimate goal is to create greater awarness, healthy 
behaviour, improved detection and enabling environments. 
 9.Procedure of the study :  
You are required to participate in this study only if you fully understand and agree to 
the requirements for the same. There will be no difference in the treatment you receive, 
nor will treatment be withheld based on your decision to participate in this study. 
The study is conducted in collaboration with medicine department. By systematic 
random sampling  108 subjects with hypertension and 28 subjects without hypertension 
will be selected from the OPD of medicine department and BP will be measured by 
auscultatory method in sitting posture. Patients who will fall under my inclusion criteria 
with BP (SBP – 140-159 mm Hg, DBP – 90-99 mm Hg),age 30-60 years,BMI 18-36 
will be recruited in this study after considering  the exclusion criteria also. All subjects 
will undergo Nerve conduction tests in the research lab in department of physiology. 
Nerve conduction study will be done by RMS EMG Machine on tibial nerve, motor 
common peroneal nerve,sensory superficial nerve and sural nerve of both limbs in 
supine posture. Study volunteers will be explained thoroughly about the procedure and 
consent will be obtained from them before the study. Detailed history including age, 
sex, height, weight, BP will be recorded. The values will be noted and it is maintained 
in case record form. Nerve conduction study recorded from Nerve conduction 
measuring system is maintained in both Microsoft office excel as well as in hard copy. 
10.Expected risks for the participant 
Each electrical stimulation is very brief and the patient will feel a tingling sensation 
which may cause little discomfort. 
11.Expected benefits of research for the participants : 
 The effect of Hypertension on Nerve conduction Parameters will be identified 
which will help in identifying the changes occurring in Peripheral Nerves due to 
Hypertension, so that the quality of life of the people will be maintained. It may be 
gratifying to know that your contributions is indispensable for the advancement of 
medical knowledge. 
12. Maintenance of Confidentiality : 
 All your study records will be kept confidential. Your personal identity will not 
be revealed in any publication or release of results. Study records will be kept 
indefinitely for analysis and follow up. 
13.Why have I been chosen to be in this study? 
 As u fall  under my inclusion criteria you have been chosen.  
14.How many people will be in the study?   128 
15.Agreement of Compensation to the participants : NIL 
16.Anticipated prorated payment,if ,any to the participant(s) of the study: 
17.Can I withdraw from the study at any time during the study period? 
 Yes, you can withdraw from the study at any time during the study period. 
18.If there is any new findings / information, would I be informed? 
 Yes, If there is any new findings / information, you will be informed. 
19.Expected duration of the participants participation in the study: one and a half 
hour 
 
 
 
20.Whom do I contact for further information 
 
 
 
 
 
 
 
 
Place : Kulasekharam      Signature of investigator 
Date : 
Dr. L. Aswathy 
Post Graduate 
Department of Physiology 
SMIMS 
Kulasekharam 
 
CONSENT FORM 
CONSENT FORM 
PART – II 
 The details of the study have been explained to me in writing and the details 
have been fully explained to me. I am aware that the results of the study may not be 
directly beneficial to me but will help in the advancement of medical sciences. I 
confirm that I have understood the study and had the opportunity to ask questions. I 
understand that my participation in the study is voluntary and that I am free to withdraw 
at any time, without giving any reason, without the medical care that will normally be 
provided by the hospital being affected. I agree not to restrict the use of any data or 
results that arise from this study provided such a use is only for scientific purpose(s). I 
have been given an information sheet giving details of the study. I fully consent to 
participate in the study titled Effect of Hypertension on Nerve conduction parameters in 
patients attending Sree Mookambika Institute of Medical Sciences, Kulasekharam. 
Name  of the participant:    Address  of the participant: 
 
 
Contact Number of the participant : 
Signature / Thumb impression of the participant/Legal guardian  
Witness 
1. 
2. 
 
Date : 
Place : Kulasekharam  
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8. Discussion  
The present study was done to assess the effect of hypertension on 
increasing BMI and age in nerve conduction study variables in patients attending 
the outpatient Department of General Medicine.The clinical procedures were 
conducted at the research laboratory in the Department of Physiology at 
SreeMookambika Institute of Medical Sciences located at Kulasekaram, 
Kanyakumari district. This study was designed to assess the effect of hypertension 
on BMI and age on nerve conduction variables since there are very few studies 
done to correlate hypertension with peripheral neuropathy, with age and BMI as 
aggravating factors. In India hypertension is the third leading killer under category 
of non-communicable disease.21 
8.1 BMI and Age: 
136 participants of the study were categorized into two main groups Control 
group and hypertensive group.This grouping was further subdivided into various 
groups based on BMI and age. Table 7 represents mean calculation of height and 
BMI in various age groups.Case History was recorded for all the 136 participants 
to verify the inclusion and exclusion criteria.The basic data such as height and 
weight were recorded from which the BMI was calculated. Mean Height and 
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MeanBMI were standardized. Onesingle mean height was chosen for the entire 
study for all the group subdivisions. 
Mean BMI was divided into four major BMI’s falling in the normal range 
19.5, Pre-obese 26.75,Obese Class I 31.5, Obese class II 35.6.This was achieved 
by following the classification of world health organization.116 The age grouping 
was subdivided into two ranges 30-45 yrs covering the younger subjects, and 50-60 
yrs covering the elderly subjects. 
8.2 Blood Pressure: 
Table 9a and 9b represents the blood pressure measurements in the age 
range 30-45 years and 50-60 years, mean BMI in both control subjects and 
hypertensive patients. In the control subjects there was significant statistical 
increase in the levels only in the age range of 50-60 yrs in the BMI 31.5(Group III 
C), and 35.6(Group III D). 
This is in contrast with the hypertension subjects where significant changes 
in blood pressure occurs in the normal range BMI of 19.5 in age 30-45 years and 
the statistical peak significance occurs in Class II Obese (Group II D) in the range 
of 30-45 years. 
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8.3 Nerve conduction studies: 
To assess the effect of hypertension on nerve conduction study variables 
along with BMI and age as co-factors; two motor nerves (Tibial and Common 
peroneal nerve) and two sensory nerves (Superficial peroneal and sural nerve) were 
studied in the control and hypertensive subjects. 
Table 10a and 10b represents the Tibial nerve conduction studies. 
In control subjects with age 30-45 years the statistical significance of latency 
and conduction velocity starts to decrease with BMI 31.5.It attains peak statistical 
significance with BMI 19.5 in the age group of 50-60 years and this peak statistical 
significance occurs in other BMI’s of 26.5,31.5, 35.6 in the age group of 50-60 
years. 
In control subjects with age 30-45 years,the statistical significance of 
duration and amplitude attains statistical significant decrease in BMI 35.6.It also 
showed statistical significant decrease with BMI 31.5 and 35.6 in age 50-60 years. 
In hypertensive subjects,with age 30-45 years,the onset of peak statistical 
significance of duration,latency, amplitude,conduction velocity occurs in BMI 
35.6. 
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In hypertensive subjects with age 50-60 years,the peak statistical 
significance of duration, latency, amplitude, conduction velocity is attained with all 
BMI groups. 
Table 11a and 11b represents the common peroneal nerve conduction 
study.In control subjects with age 30-45 years the statistical significance of 
duration,latency,amplitude,conduction velocity starts to decrease with BMI31.5 
and also showed statistical significant decrease in BMI 35.6. 
In control subjects with age 50-60 years the statistical significance of 
duration,latency,amplitude,conduction velocity occurs in all BMI  groups of 
19.5,26.75,31.5,35.6. 
In hypertensive subjects ,with age 30-45 years,the statistical significance of 
duration,latency, amplitude ,conduction velocity is seen in BMI 26.75.The peak 
statistical significant decrease is obtained in BMI 35.6.This peak statistical 
significance is sustained in all BMI groups with age 50-60 years also. 
Table 12a and 12b represents the superficial  peroneal nerve conduction 
study.In control subjects with age 30-45 years the statistical significant decrease 
ofduration,latency, amplitude ,conduction velocity occurs with BMI 31.5.This 
significance is maintained with BMI 35.6 in the same age group.It attains peak 
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statistical significant decrease in BMI 26.75, 31.5, 35.6 in age group of 50-60 
years. 
In hypertensive subjects with age 30-45 years the statistical significance is 
attained with BMI  26.75.The peak statistical significance decrease of 
duration,latency,amplitude,conduction velocity is attained with BMI 31.5,35.6 in 
the same age group of 30-45 years. 
In hypertensive subjects with age 50-60 years the peak statistical significant 
decrease ofduration,latency,amplitude,conduction velocity is obtained with BMI 
26.5, 31.5, 35.6. 
Table 13a and 13b represents the sural nerve conduction study.In control 
subjects with age 30-45 years the statistical significance ofduration,latency, 
amplitude ,conduction velocity  attains statistical significance with BMI 31.5.This 
statistical significance is maintained withBMI of 35.6 in the same age group.Also 
thisstatistical significance is maintained in age 50-60 years with other BMI’S of 
19.5, 26.5, 31.5, 35.6. 
In hypertensive subjects with age 30-45 years the statistical significance of 
duration,latency,amplitude,conduction velocity is obtained with BMI 26.75.The 
peak statistical significance is obtained with BMI’s 31.5, 35.6 in the same age 
group of 30-45 years. 
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In hypertensives with age 50-60 years peak statistical significance of 
duration,latency, amplitude, conduction velocity is obtained with BMI 
19.5,26.5,31.5, 35.6. 
Though certain papers report a negative association between hypertension 
and peripheral neuropathy96,97, Our study presents a positive correlation  between 
hypertension and peripheral neuropathy. However, there are studies that present a 
positive correlation between hypertension and nerve conduction studies by Dhafir. 
I El-Yassinet. al.51  BMI and age related studies done by Awang et al99 observed 
that with increasing BMI and age in control subjects there is slowing of nerve 
conduction velocity in median (both motor and sensory) nerve with increasing 
BMI and age. 
Another study published in the Indian J. PhysiolPharmacol in 2012 by Pawar 
SM et al.117 has also similar findings related to our study. They report prolongation 
of distal motor latency with increasing BMI. They also observed F-wave minimum 
velocity which was significantly prolonged in motor tibial nerve. 
Dhafir I. El- Yassin51 has clinically proved a positive correlation between 
hypertension and nerve conduction velocity and reports that patients with 
hypertension present peripheral sensory neuropathy mainly of axonal type with  
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demyelination as an secondary outcome only in the sural nerve. 
In our study demyelination and axonal changes are observed as alterations in 
the nerve conduction study variables such as CMAP or SNAP latency and 
amplitude.The changes in hypertension occurs at a relatively earlier age range of 
30-45 years with  BMI 26.75. In the control subjects, the changes occurs in the 
same age range of 30-45 years  butwith a higher BMI. These results are in 
agreement with Dhafir I. El- Yassin’s paper.51 
8.4 Molecular Pathophysiology Pertaining To Nerve Conduction Variables 
Though we have a clear understanding that BMI and age can cause deficits 
in nerve conduction variables in control subjects; the presence of hypertension in a 
subject along the with age and BMI as co-factors could aggravate the deficits in 
nerve conduction variables at an earlier age when compared to control subjects 
thus making them prone to present with peripheral neuropathy. 
Though our study has not included much pathophysiology experiments we 
were interested in finding a basic working on molecular pathophysiologic 
mechanism that would enlighten us on what is the process of BMI and age in 
reducing the nerve conduction variables. 
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We hypothesize that hypertension mediated dyslipidemia can cause 
oxidative stress that in turn imbalances Angiotensin II and vasodialator balance 
especially nitric oxide and endothelin-1. The process is continued as a feed forward 
mechanism since the antioxidant status is compromised due to oxidative damage to 
the antioxidant enzymes and the presence of high volume of free radicals being the 
primary culprits of oxidative stress. 
Depletion of Nitric oxide is an outcome of oxidative stress which mediates 
the production of peroxynitrite a biological reaction of nitric oxide with single 
oxygen (free radical). The formation of peroxynitrite and free radicals and 
depletion of antioxidants mediate the activation of aging mechanisms such as 
senescence and apoptosis that culminate into axonal degeneration observed as 
CMAP or SNAP amplitude decrease with prolongation of duration in control and 
hypertensive subjects and this  occurs at earlier stage in the hypertensive subjects. 
This is possibly due to onset of oxidative stress at an earlier stage and its non-
depletion,despite various therapies targeted on hypertension. 
Axonal degeneration or apoptosis of the nerve occurs as an outcome of 
oxidative stress mediated by Poly-ADP-ribose polymerase [PARP], an death 
enzyme present within the Axon. 
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Demyelination is an outcome of degeneration of myelin which is also 
achieved by oxidative stress implementing uncontrolled and irreversible lipid 
peroxidation causing the degradation of  myelin which causes latency changes in 
the nerve conduction. 
Finally the Na+K+ATPase at the nodes of Ranvier 0 also lose its 
functionality due to deprivation of ATP that is an outcome of inefficient 
mitochondrial functioning during the onset of Axonal degeneration. 
All these processes finally culminate into functionally defective nerve, 
incapable of firing; and is witnessed clinically as peripheral neuropathy in the 
peripheral nerves in hypertension. 
Crowley SD 118 and Yasunari K et al119 have proved clinically that oxidative 
stress is an outcome of chronic inflammation in hypertensive subjects. The onset of 
oxidative stress in hypertensive subjects depletes the levels of nitric oxide via the 
formation of peroxynitrite. This mechanism has been clinically proved by Moriel P 
et al120.  
Peroxynitrite mediated activation of PARP has been experimentally been 
proved in spontaneously hypertensive rats by Dereset al.121. The association of 
PARP activity mediating axonal degeneration has been experimentally proved in a 
rat model of multiple sclerosis by Penberty WT and Tsunoda I122; and the presence 
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of axonal degeneration in hypertension has been proved experimentally in SHR 
rats by Sanada LS et al123. SHR rats are molecular mimics of essential hypertension 
and they serve as good counterpart in working the mechanisms behind essential 
hypertension that cannot be done in human subjects. 
Our study clearly demonstrates, axonal degeneration as changes in CMAP or 
SNAP amplitude and prolongation in duration in control subjects with higher BMI 
and age, whereas, in the essential hypertensives changes occurred in lower age 
range with increasing BMI. 
Demyelination was also observed as latency changes in our study following 
the same trend of onset in control and hypertensive subjects as indicated for axonal 
degeneration. 
Our findings are supported by clinical studies of Henry C. et al124, who has 
studied the effect of aging on sensory nerve conduction parameters and has 
presented that sensory nerve conduction velocity does change with aging.  
Aging mechanisms have experimentally proved in hypertension by                
Kung CF et al125 
  Discussion 
 
109 
 
Demyelination is observed as latency changes with increasing BMI and age 
which has been clinically proved by Awanget al99 and experimentally it has been 
proved by Sanada LS et al.123 
 
 
 
Figure.1 Mechanism of Oxidative stress Mediated Neurol degeneration in 
health and Disease 
 
Image 1: Computerised RMS ALERON 401 EMG/NCV/EP System 
 
 
 
 
 
